CA2221570A1 - Neutralizing conformation epitopes of chicken anemia virus - Google Patents
Neutralizing conformation epitopes of chicken anemia virus Download PDFInfo
- Publication number
- CA2221570A1 CA2221570A1 CA002221570A CA2221570A CA2221570A1 CA 2221570 A1 CA2221570 A1 CA 2221570A1 CA 002221570 A CA002221570 A CA 002221570A CA 2221570 A CA2221570 A CA 2221570A CA 2221570 A1 CA2221570 A1 CA 2221570A1
- Authority
- CA
- Canada
- Prior art keywords
- cav
- virus
- neutralizing
- recombinant
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000003472 neutralizing effect Effects 0.000 title claims abstract description 72
- 241000725585 Chicken anemia virus Species 0.000 title claims abstract description 23
- 239000013598 vector Substances 0.000 claims abstract description 40
- 241000700605 Viruses Species 0.000 claims abstract description 34
- 229960005486 vaccine Drugs 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 17
- 101710108545 Viral protein 1 Proteins 0.000 claims description 77
- 210000004027 cell Anatomy 0.000 claims description 62
- 108090000623 proteins and genes Proteins 0.000 claims description 43
- 241000701447 unidentified baculovirus Species 0.000 claims description 35
- 239000002245 particle Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 18
- 230000014509 gene expression Effects 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 239000003623 enhancer Substances 0.000 claims description 9
- 230000002068 genetic effect Effects 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 238000011321 prophylaxis Methods 0.000 claims description 5
- 238000013518 transcription Methods 0.000 claims description 5
- 230000035897 transcription Effects 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 238000002405 diagnostic procedure Methods 0.000 claims description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 101000714457 Chaetoceros protobacilladnavirus 2 Capsid protein Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 33
- 239000012634 fragment Substances 0.000 abstract description 12
- 230000001681 protective effect Effects 0.000 abstract description 11
- 230000028993 immune response Effects 0.000 abstract description 9
- 230000001717 pathogenic effect Effects 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 5
- 238000001514 detection method Methods 0.000 abstract description 4
- 229940031626 subunit vaccine Drugs 0.000 abstract description 4
- 108020004511 Recombinant DNA Proteins 0.000 abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 229940031567 attenuated vaccine Drugs 0.000 abstract 1
- 101710081079 Minor spike protein H Proteins 0.000 description 116
- 108020004414 DNA Proteins 0.000 description 34
- 102000004169 proteins and genes Human genes 0.000 description 32
- 101000805768 Banna virus (strain Indonesia/JKT-6423/1980) mRNA (guanine-N(7))-methyltransferase Proteins 0.000 description 28
- 101000686790 Chaetoceros protobacilladnavirus 2 Replication-associated protein Proteins 0.000 description 28
- 101000864475 Chlamydia phage 1 Internal scaffolding protein VP3 Proteins 0.000 description 28
- 101000803553 Eumenes pomiformis Venom peptide 3 Proteins 0.000 description 28
- 101000583961 Halorubrum pleomorphic virus 1 Matrix protein Proteins 0.000 description 28
- 241000287828 Gallus gallus Species 0.000 description 23
- 235000013330 chicken meat Nutrition 0.000 description 21
- 230000002238 attenuated effect Effects 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 17
- 241000238631 Hexapoda Species 0.000 description 14
- 210000000234 capsid Anatomy 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 10
- 230000002458 infectious effect Effects 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 208000007502 anemia Diseases 0.000 description 7
- 238000010166 immunofluorescence Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000006386 neutralization reaction Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 101710182846 Polyhedrin Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 241000271566 Aves Species 0.000 description 3
- 241000948165 Milk vetch dwarf virus Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009585 enzyme analysis Methods 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000008774 maternal effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000000869 mutational effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 101710094856 Apoptin Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000700662 Fowlpox virus Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 2
- 101710204410 Scaffold protein Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241001302800 Beak and feather disease virus Species 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241001533399 Circoviridae Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101150032643 IVa2 gene Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000006758 Marek Disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000202347 Porcine circovirus Species 0.000 description 1
- 101710136297 Protein VP2 Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- -1 VPl Proteins 0.000 description 1
- 206010046862 Vaccination failure Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000010218 electron microscopic analysis Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 238000003126 immunogold labeling Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940024231 poxvirus vaccine Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 229960001407 sodium bicarbonate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16341—Use of virus, viral particle or viral elements as a vector
- C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10061—Methods of inactivation or attenuation
- C12N2750/10062—Methods of inactivation or attenuation by genetic engineering
Abstract
The production of the conformational neutralizing epitope of chicken anemia virus is described and compositions for preventing or treating CAV infections, in particular vaccines less pathogenic than CAV itself. All these compositions were shown to synthesize the conformational neutralizing epitope, necessary for the protective immune response against CAV infections. The invention provides recombinant DNA molecules derived from the CAV genome, and recombinant DNA fragments of the CAV genome integrated in the genome of other virus vectors. In particular, these compositions comprise a sub-unit vaccine, a recombinant live virus vaccine and an attenuated vaccine against CAV
infections. The invention also provides the production of neutralizing antibodies directed against CAV and diagnostic kits for the detection of CAV.
infections. The invention also provides the production of neutralizing antibodies directed against CAV and diagnostic kits for the detection of CAV.
Description
Title: Neutr~ ;ng conforma~; n~l epitopes of Ch; ck~n anemia virus .
BRIEF DESCRIPTION OF T~ lNv~NllON
The present invention provides the formation and characterization of the ..~Ll-li~;ng conforma~;~Al epitope of the CAV protein VPl, which is required for eliciting a protective Lmmune ~e~u~l~e in vA~c;nAted animals.
In par~ l1 Ar, the production of ll~uL~ ;ng an~; h~; ~5 againt CAV is descr; h~ . In a diagnostic test, based on these produced neutrAl;~;ng ant;ho~;~s, CAV
(part;~l~s) are detected.
Various vA~c;n~ ve~Lo~ A;nct CAV infections are ~;cclnsed~ All these vACc;n~c are less pa~h~en;~ than CAV. All these vA~;n~ vector are shown to ~ u~e the required neutr~ ;n~ confol~t;onAl epitope of CAV.
One vector provides a subunit vA~c;n~, based on a recombinant baculovirus expressing both VPl and VP2 in the same cell. A second type of vA~c;n~ is a live virus vector, comprising a Marek's disease vector stably h~rhoring the coA;ng se~n~c for VPl and VP2. The third CAV vA~C;ne comprises genet;~lly attenuated CAV str~;ns with a reduced cytopathogenic effect.
BACRGROUND OF THE lNv~NllON
Chicken An- ~A virus (CAV) is a sm~ll virus of a unique type with a particle diameter of 23 to 25 nm and a genome consisting of a circular c; n~l e-stranded (m;nus-strand) DNA (Gelder blom et al., 1989, No~hnrn et al., 1991 and Todd et ~l., 1990). This DNA mult.;rl;~5 in infected cells via a circular ~ hle-stranded replicative intermediate, which was L~l.Lly clon~ and fully se~-~n~e~. The CAV genome is 2319 nucleotides long (Not~h~rn and De Boer, 1990). DNA analysis of CAV strains isolated in different continents revealed only m;nor 5UBSTITUTE SHEET (RULE 26) CA 02221j70 1997-12-Oj differences among the various isolates (Meehan et al., 1992; accession number M81223, Claessens et al., 1991;
D10068, Kato et al., 1995; D31965 and Pallister et al., 1994 Soine et al. 1993 and 1994; L14767). Recently, on the basis of the genome structure, CAV has been placed into the novel virus family of Circoviridae. However, CAV is not related to the other members of this virus family consisting of ~n;m~l single-stranded circular-DNA viruses, such as porcine circovirus and psittacine beak-and-feather-disease virus (Noteborn and Koch, 1995).
The CAV genome contains one evident promoter/enhancer region (Noteborn et al. 1994) which regulates the CAV
transcription. The major transcript from the CAV genome is an unspliced polycistronic mRNA of about 2100 nucleotides encoding three proteins of 51.6 kDa (VPl~, 24.0 kDa (VP2) and 13.3 kDa (VP3 or apoptin (Noteborn and Koch, 1995, Noteborn et al., 1992 and Phenix et al., 1994). All three predicted CAV proteins are synthesi zed in CAV-infected cells (Noteborn and Koch, 1995). Tmmlln;zation with (recombinant) VPl and VP2 synchronously synthesized in the same cells elicits a protective response and can be used as subunit vaccine against chicken infectious anemia (Koch et al., 1995 and Noteborn and Koch, 1994c).
CAV causes clinical and subclinical disease in chickens, and is recognized as an important avian pathogen worldwide (McIlroy et al., 1992 and McNulty et al., 1991).
Day-old chicks are especially susceptible to CAV
infections. In these ~n;m~l S lethargy, anorexia and anemia are observed from 10 days after inoculation with CAV.
After infection mortality may increase to a m~; mllm of 50%. With increasing age the resistance also increases (Jeurissen et al., 1992). The hematocrit values of chicks that had been infected with CAV at an age of 1-3 days are decreased. CAV infections of 1-21 days old chicks result in a depletion of in partlcular the thymus cortex.
However, in older chickens CAV can subclinically multiply.
CA 0222l~70 l997-l2-0~
WO96/40931 PCT~L96/00230 CAV infection in older-chickens can be determined by the occurence of seroconversion.
The depletion of the cortical thymocytes is considered to cause immunodeficiency resulting in enhanced concurrent infections and to vaccination failures (Noteborn and Koch, 1995). The depletion of thymocytes and most likely also of erythroblatoid cells occur via CAV-induced apoptosis (Jeurissen et al., 1992a). The CAV-encoded protein apoptin is the main inducer of this phenomenon (Noteborn et al., 1994).
Maternal antibodies have been found to give an important protection against CAV infection. Vielitz et al.
(1991) reported that hens exposed to CAV from large amounts of antibodies, which are passively transferred to the offspring per ovum. These antibodies protect against chicken infectious-anaemia-associated disease.
CAV-neutralizing antibodies were detected in yolk of eggs produced by hens that had been inoculated with lysates of cells that had been co-infected with CAV-recombinant baculovirus and produced all three CAV proteins, or mainly VP1 and VP2. Specific clinical signs did not develop in CAV-challenged progeny that hatched from these eggs (Koch et al., 1995).
Vielitz and Landgraf (1988) have developed a vaccine against infectious anaemia, which is based on CAV
propagated in chicken embryos. Currently, this is the only commercially available vaccine. The offspring of vaccinated breeders are protected againt infectious anaemia. Vaccination is possible because when maternal immunity vanished, the birds are susceptible to virus infection without developing the disease. Obviously, the use of live vaccines based on non-attenuated virus harbors risks. Experimental infection of 3-week-old chickens resulted in a comprehensive decrease of the functions of the immune system (McConnell et al., 1993, and 1993a) in the absence of disease. In line with this finding, McIlroy (1992) have provided evidence that CAV also causes CA 0222l~70 l997-l2-0~
WO96/40931 PCT~L96/00230 considerable economic losses in the absence of disease:
the subclinical disease negatively affected feed conversion and average body weight and increased medication, both of which result in a considerable financial burden. So far, non-pathogenic CAV has not been isolated.
The recombinant CAV proteins synthesized by means of the baculovirus expression system can be used as a subunit vaccine. The recombinant CAV proteins VPI and VP2 have been proven to protect chicks by maternal immlln-ty (Koch et al, 1995). Since the baculovirus vector is an insect-specific virus, known to be non-pathogenic for vertebrates, it can be cultured and supplied to chicken without undue risks ~Vlak and Keus, 1990).
In general, live-virus vaccines induce a better immune response and are less expensive than sub-unit vaccines. Therefore, knowledge about the immunogenicity of the various CAV proteins can be used to construct attenuated CAV or other recombinant-virus vectors, such as avian herpes viruses (Nakamura et al., 1992, Morgan et al., 1993) or fowlpox virus (Nazerian et al., 1992, Boyle and Heine, 1993). These recombinant viruses should express the CAV protein VPl and VP2, in addition to their own proteins, and may be applicable as vaccine for both layer breeders and broiler breeders to protect their offspring against infectious anaemia. In addition, such vectors may be used to protect maternally immune broilers against subclinical disease.
DETAILED DESCRIPTION OF THE INVENTION.
The present invention relates to production and analyses of the neutralizing conformational epitope structure of chicken anemia virus (CAV).
Furthermore, the production of neutralizing monoclonal antibodies directed against CAV is disclosed.
It is shown that these neutralizing antibodies are CA 02221~70 1997-12-o~
WO96/40931 PCT~L96/00230 directed against a conformational epitope of CAV protein VPl.
Also a diagnostic test kit, based on these neutralizing antibodies, for the detection of CAV will be described. This invention provides evidence for the me~h~nism by which the neutralizing antibodies neutralize CAV particles.
For the formation of the neutralizing conformational epitope of VPl, the synthesis of VP2 within the same cell is required. Recombinant baculovirus expressing only VPl in insect cells only does not react with neutralizing antibodies directed against CAV, but these neutralizing antibodies will react when VPl and VP2 are synthesized in one cell.
In purified CAV capsids, however, only VPl is present. This invention discloses that during the synthesis of VPl, and most likely during its complex formation resulting in the CAV capsids, VP2 binds temporarily to VPl. Denaturation of the CAV capsids results in the destruction of the neutralizing epitope, indicating that the neutralizing epitope is an conformational one.
Besides, the invention relates to vaccines and compositions for preventing or treating virus infections in poultry, in particular infections with CAV.
In particular, the invention relates to vaccines that are less pathogenic than the CAV itself but are still capable of producing the neutralizing conformational epitope. Vaccination of chickens with these type of vaccines will lead to the generation of neutralizing antibodies and thus protect the ~ n; m~ and their progeny against CAV infections.
The invention relates to a baculovirus vector which contains separately on its genome the coding sequences for VPl or VP2. This recombinant baculovirus is able to synthesize VPl and VP2 in the same cell, resulting in the CA 0222l~70 l997-l2-0~
W096/40931 PCT~L96/00230 formation of the neutralizing conformational epitope of CAV.
The invention also relates to the construction of a Marek's~disease virus (MDV) vectors cont~in;ng CAV
sequences encoding VP1, VP2 proteins. In particular, this recombinant MDV vector synthesizes the recombinant CAV
proteins in such a way that the neutralizing conformational epitope of VP1 is properly made.
Furth~rmnre, the invention describes the formation of various attenuated CAV strains, which reveals a reduced cytopathogenic effect in chicken T cells in comparison to a a wild-type-derived CAV strain. The attenuated CAV
strains were made by introducing point mutations in a cloned CAV DNA genome, in particular a sequence within the promoter/enhancer region has been mutated. The attenuated CAV mutant strains are able to produce the neutralizing conformational epitope.
Processes for the prophylaxis or control of CAV
infections, in particular in chickens, and processes for the preparation of recombinant parts of CAV comprising sequences, and processes for the preparation of vaccine are also subjects of the invention.
Thus, reiterating the invention provides a neutralizing antibody or an antibody fragment or derivative thereof reacting with a conformational epitope of viral protein 1 (VP1) of chicken anaemia virus (CAV) recognized by a monoclonal antibody designated as 132-1, 132-2 or 132-3, as produced by the hybridoma's deposited under no.'s xxxxxx, yyyyyy, zzzzzz at the Insitut Pasteur, Paris, France. A workable experiment for det~rmining whether an antibody is an antibody according to the invention is to see if it cross-reacts (or competes) with an antibody from the deposited hybridomas. Fragments and derivatives of antibodies are well known in the art and hardly need further explanation for the person skilled in the art.
CA 02221~70 1997-12-0~
The invention also provides a conformational neutralizing epitope of viral protein 1 of chicken anaemia virus recognized by an antibody as disclosed above. The epitope may be part of a larger molecule, it may for 5 instance be bound to a carrier or the epitope may be & repeated (at intervals) in a polypeptide chain. Preferably the epitope is part of a larger part of VPl, because such a molecule will have the right conformation more easily.
As described the conformational epitope will only be 10 present on VPl if it is produced in one cell, preferably from one vector together with VP2. Therefore the.invention provides a method for producing a viral protein 1 comprising a conformational epitope as disclosed a~ove, comprising the expression of said viral protein 1 in one 15 cell together with viral protein 2 of said CAV whereby the genetic information encoding VP1 and the genetic information encoding VP2 are separately present on one recombinant vector.
The invention also includes vectors for use in a 20 method just described comprising as two separate coding sequences the genetic information encoding VP1 and the genetic information encoding VP2. Preferably such a vector is based on Marek's disease virus vector so that a vaccine can be produced giving protection against two pathogens.
A very safe and efficient expression system for the viral proteins according to the invention are vectors which are based on a baculo virus vector. As explained before Baculovirus is generally regarded as safe for use in vertebrates since it cannot infect them.
The invention also provides another way of arriving at vaccines or vaccine components which do have the very important neutralizing comformational epitope, but have reduced pathogenicity. (Attenuated viruses for instance.) This is achieved by providing a method for providing a viral protein 1 comprising a neutralizing conformational epitope according to the invention, comprising expressing at least a functional part of VP1 and VP2 from genes CA 0222l~70 l997-l2-0~
WO96/40931 PCT~L96/00230 encoding them, at least one of which genes is under control of a regulatory sequence derived from the CAV
sequence upstream of the transcription intitiation site which regulatory sequence is modified to reduce its efficiency. In this way recomnbinant viruses can be produced which do not replicate as fast and therefor are less pathogenic ~i.e. attenuated).
Such virus particles are also part of the invention.
As disclosed hereinbefore the modification is preferably in the promoter/enhancer region and most preferably the modification is in the 12 base pair insert in the promoter enhancer region.
Recombinant virus particles obtainable by any method according to the invention are also part of the invention, as are nucleic acids for use in any method according to the invention, for instance vectors comprising a gene encoding at least a functional part of VPl and a gene encoding a functional part of VP2, at least one of the genes being inder control of a regulatory sequence which is modified to reduce its efficiency.
The antibodies and epitopes according to the invention are also useful in a diagnostic test kit for detecting or det~rmining the presence of CAV or antibodies to CAV in a sample Furthermore vaccines for the treatment or prophylaxis of CAV associated disease comprising an antibody or an epitope according to the invention together with a suitable adjuvans and/or a suitable vehicle for administration are also provided herewith as are vaccines for the treatment or prophylaxis of CAV associated disease comprising recombinant virus particles according to the invention together with a suitable adjuvans and/or a suitable vehicle for a~min;ctration.
The invention will be explained in more detail on the basis of the following experimental part. This is only for the purpose of illustration and should not be lnterpreted as a limitation of the scope of protection.
CA 0222l~70 l997-l2-0~
W096/40931 PCT~L96/00230 EXPERIMENTAL
Purification of CAV particles to elicit neut~alizing mo~oclonal antiho~ies aga;n.~t CAV
For the production of neutralizing monoclonal antibodies against CAV, mice were injected with purified CAV particles.
The supernatant of a 1-liter culture of CAV-infected MDCC-MSB1 cells was fourty times concent~ated by means of a MILLITAN 300-kDa filter (Millipore, USA). The supernatant was dialyzed against lOmM Tris(ph 8.7)-lmM
EDTA (TE) buffer. Subsequently, sodium dodecyl sulphate (SDS) to an end-concentration of 0.5% was added to the CAV-capsid suspension and incubated for 30 minutes at 37 C. Finally, the CAV capsids were pelleted on a 30%
sucrose cushion. The pellet cont~;n;ng the CAV capsids was resuspended in 1 ml TE buffer. Mice were twice injected with 100 ~ul CAV-capsid suspension.
In-vitro neutralization test.
The supernatants of the candidate monoclonal antibodies were diluted 1:2 and then a two-fold dilution series was made. The diluted supernatants were incubated for 1 hour with 104-105 TCID50 CAV-Cux-1 (Von Bulow et al., 1983, Von Bulow, 1985). Approximately one hundred thousand cells of the T cell line MDCC-MSB1 transformed by Marek's disease virus were infected with this mixture of diluted supernatant and virus (Yuasa, 1983, Yuasa et al.
1983).
Tmmllnofluorescence and immunoperoxidase assay Cells were fixed with 80~ acetone and used for immunofluorescence assays with CAV-specific monoclonal antibodies and goat anti-mouse IgC conjugated with fluorescein, as decribed by Noteborn et al. (1990).
CA 0222l~70 l997-l2-0~
WO96/40931 PCT~L~6,0~230 Recombinant-Vpl/VP2-MDV-infected CEF were used for immunoperoxidase stai ning with CAV-pecific monoclonal antibodies, as described by Jeurissen et al. (1988).
5 EnzymP-l;nked ;mml~nosorh~n~ assay f~TISA~
Microtiter wells (Greiner~ FRG) were coated with the CAV-specific neutralizing monoclonal antibody 132.1, which was 1:10,000 diluted in 50 mM sodiumbicarbonate pH 9.6.
Wash the wells three times with tapped water cont~;n;ng 0.05% Tween 80. Saturate the wells with 100 ~ul phosphate-buffered saline cont~;n;ng 4% horse serum, 51 gram/liter NaCl, and 0.05% Tween 80 (saturation buffer) for 30 minutes at 37 C. Wash the wells three times with tap water containing 0.05% Tween 80. Next, 50 u~l of non-diluted chicken serum and 50 ~ul of thirty times concentrated supernatant containing CAV particles, or 50 ~ul of a lysate of insect cells containing recombinant VP1 and VP2 proteins, were mixed, added per well and incubated for 1 hour at 37 C. Wash the wells three times with tap water containing 0.05% Tween 80. Add per well 100 u~l a 1:2000 fold dilution of a peroxidase-labeled rabbit an ti-mouse immunoglobulin G conjugate in saturation buffer.
Incubate for 1 hour at 37 C. Wash again three times with tap water containing 0.05% Tween 80. Add 100 ~1 of a standard solution of tetramethylbenzidine, sodiumacetate and hydrogenperoxidase to the wells and incubate for 10 minutes at room temperature. The reactlons are blocked with 10~ H2SO4. The various wells are ~m; ned at 450 nm, as standard.
Baculovirus ,~nd i~ect cells.
The recombinant baculovirus AcRP23-lacZ (Bishop, 1992) was obtained from Dr. R. Possee, NERC Institute of Virology, Oxford, England, and the genomic DNA was purified as described by Summers and Smith (1987).
Spodoptera frugiperda (Sf9) cell were obtained from the American Tissue Culture Collection (no. CRL 1711).
CA 0222l~70 l997-l2-0~
Baculovirus stocks were grown in confluent monolayers and suspension cultures in TC-100 medium (GIBCO/BRL) containing 10% fetal calf serum, as described by Summers and Smith (19~7).
Clon; nq of CAV DNA.
All CAV DNA sequences are originally derived from the plasmid DNA pIc-20H/CAV-EcoRI (Noteborn and De Boer, 1990). All cloning steps with plasmid DNA were in principle carried out according to the methods described by Maniatis et al. (1982).
DNA transformations were carried out in the E.coli strain HB101. All plasmid were multiplied in large culture under agitation, purified on CsCl gradients, and then by filtration over Sephacryl-S500 columns or by filtrations on QIAGEN-chromatography columns.
Conctruct;on ~n~ 5~lect;0n of rec~mh;nAnt-VPl/VP2 bacl1lovirus.
Recombinant transfer vector pAcVP1/VP2 DNA was transfected with linearized recombinant baculovirus AcRP23-lacZ DNA, in Sf9 cells. After homologous recombinantion baculoviruses were obtained, which had incorporated in the polyhedrin unit instead of the lacZ
the two CAV proteins VP1 and VP2 under regulation of the promoter of the plO or polyhedrin gene, respectively. In first instance, the recombinant CAV viruses were characterized for the absence of beta-galactosidase activity in plaques of baculovirus-infected insect cells.
Further the integration of CAV DNA sequences in the baculovirus genome was det~r~;ned by means of a CAV-specific DNA probe in a hybridization experiment.
Immunoprecipitation assay Two days after infection, the cells were incubated with Promix label (ICN, USA~ and four hours later, the cells were lysed in ElA buffer (50 mM Tris (pH7.5), 0.1 CA 02221~70 1997-12-0~
WO96/40931 PCT~L96/00230 Triton-X-100, 250 mM NaCl, 50 mM NaF, and 5 mM EDTA) and incubated with monoclonal antibody 111.1 directed against VP2 for 2 hours at 4 C, washed with ElA buffer and separated on a PAA-SDS gel.
Tr~n~fection of ~nv DNA ;n ~s.
For the construction of recombinant-VP1/VP2 MDV, co-transfections with purified recombinant-VP1/VP2 MDV-transfervector and DNA, isolated from chicken embryo fibro blasts (CEF) infected with MDV Rispens isolate (van Vloten et al. 1972) were carried out according the method described by Graham and Van der Eb (1973).
~ansfection of chicken T cells with mutant-CAV ge~omes.
The various mutated-CAV clones were digested with EcoRI and the EcoRI fragmerlts cont~; n; ng the CAV (mutated) sequences was recircularized and transfected in MDCC-MSB1 cells, by using the DEAE-dextran method as has been described by Noteborn et al. (1991). As control, the whole procedure was in parallel carried out for the pCAV-EcoRI
clone.
RESULTS AND DISCUSSION
The production of neutralizing monoclonal antibodies against CAV.
Noteborn and Koch (1994) have described two types of CAV-specific monoclonal antibodies. One type is directed against VP2, while the other is directed against VP3. None of these monoclonal antibodies reveal a CAV-specific neutralizing activity. Even, more important was that none of these monoclonal antibodies was directed against VP1.
We assumed that a neutralizing monoclonal antibody might be directed against VPl, for the capsids contain mainly VPl (Todd et al., 1990). Below, we describe the production of neutralizing antibodies against CAV.
CA 0222l~70 l997-l2-0~
WO 96/40931 PCT/NL~)6/0~0 For the production of neutralizing monoclonal antibodies against CAV, mice were injected with purified CAV particles.
As a first screening for (neutralizing) monoclonal antibodies against CAV, microtitre wells were coated with recombinant-VP1/VP2-baculovirus infected insect cells, which co-synthesized both VP1 and VP2 (see below).
CAV-specific antisera with a high neutralizing titer reacted at a dilution of 1:1000 specifically with the recombinant VPl and/or VP2 products (see below). Several different hybridoma cell lines producing monoclonal antibodies, which specifically reacted with recombinant VP1/VP2 products, were obtained.
A CAV-specific serum neutralization test, showed that three of these monoclonal antibodies obtained, had a neutralizing activity against CAV. These three CAV-specific neutralizing monoclonal antibodies were called 132.li 132.2 and 132.3.(deposited under no's xxxx,yyyy,zzzz at the Institut Pasteur, France.
Microscopy examinations of the neutraliz;ng monoclonal antibodies d~ ected aga;n~t CAV.
Immunofluorescence showed that the three neutralizing monoclonal antibodies 132.1, 132.2 and 132.3 recognize specific structures in CAV-infected MDCC-MSBl cells. None of these monoclonal antibodies reacted with uninfected MDCC-MSB1 cells.
Electron-microscopic analysis was carried out with purified CAV particles incubated with neutralising antibodies against CAV (132.1) or with monoclonal antibodies 111.1 (against VP2) or 111.3 (against VP3).
Todd et al. (1990) have reported that purified CAV capsids contain onlya 50-kDa protein, which is most likely VPl.
The various monoclonal antibodies were detected by immunogold labeling. Only the neutralizing monoclonal antibodies 132.1 were found to bind to CAV particles.
Binding of the monoclonal antibody 132.1 to a CAV particle CA 0222l~70 l997-l2-0~
WO96/40931 PCT~L96/00230 resulted in its lysis. Furth~rmorer CAV capsids, which were lysed due to incubation with the neutralising monoclonal antibody 132.1, showed no binding with monoclonal antibo dies directed against VP2 or VP3.
These results reveal the mech~n; ~m by which the neutralizing monoclonal antibodies act: They cause the lysis of the virus capsids, by doing so causing non-infectious particles. Furthermore, these data show that purified CAV particles contain (almost) only VP1.
Neutr~l;z;ng ~noclon~l anl-;hodies are directed aaain~t an conformation~l epitope on VP1.
Pepscan analysis (Geysen et al., 1984) revealed that none of the 3 neutralizing monoclonal antibodies reacted significantly with one of the 12-mers derived from VP1 or VP2, or VP3. For the sake of brevity only the data obtained wwith monoclonal antibody 132.1 are shown for VPl in Figure 1, and for VP2 in Figure 2. These results indicate that the neutralizing monoclonal antibodies are directed against a conformational epitope.
These data were confirmed by the following experiments. Purified CAV particles, dotted on a nylon filter under native conditions, still could react with the neutralizing monoclo nal antibody 132.1. However, after boiling in the presence of SDS, the CAV capsid proteins did not bind to monoclonal antibody 132.1.
Immunoprecipitations experïments, carried under native conditions, as described by Noteborn et al.
(1994b), with partially purified CAV particles and monoclonal antibody 132.1, 132.2 or 132.3 showed that a protein of about 50 kDa was precipated by these monoclonal antibodies.
It can be concluded that the presented results indicate that the neutralizing monoclo nal antibodies are directed against an conformational epitope of VP1.
CA 02221~70 1997-12-0~
~nzyme-linked ;mm~lnosorbens assay (~TISA) based on 2 neutralizina antibody againct CAV.
We have developed a complex-trapping-blocking ~ ~CTB)-ELISA. One can use enriched CAV particles derived from CAV-infected MDCC-MSB-1 cells or recombinant VPl/VP2 proteins synthesized by means of the above described baculovirus system.
Serum from CAV-infected chickens contains antibodies which will block all epitopes on the CAV capsids.or recombinant VP1/VP2. This means that the CAV capsid or recombinant VPl/VP2 will not bind to the coated monoclonal antibody 132.1. Negative serum, howe ver, will allow binding of CAV capsids or recombinant VPl/VP2 to the coated 132.1. A signal smaller than 0.5 of the signal detected with a negative control serum will be ~m; ned as positive.
The detection level of our CTB-ELISA are titers of 24 to 25 a det~rm;ned in a serum neutralization test, which is very sensitive. More than 400 sera were analyzed.
Comparison to the serum neutralization test revealed that 96.5% of the positive sera within the serum neutrali zation test were positive within the CTB-ELISA, and 98.3%
of the negative sera within the serum neutralization test were negative within the CTB-ELISA.
Construction of a recom~;n~nt-VPl/VP2 transfer vector.
The coding sequences for the CAV proteins VPl and VP2 were cloned into the baculovirus transfer vector pAcUW51 (cat. no: 21205P), which was co~-rcially obtained from PharMingen, San Diego, USA. This vector is shown in Figure 3 and contains the polyhe drin flanking region, within their midst the baculovirus polyhdrin promoter and the plO
promo ter and for both transcription units, the required 3'-non-coding transcrioptional sequences including the polyadenylation signals. The transfer vector contains prokaryotic sequences for multiplication in bacteria.
CA 0222l~70 l997-l2-0~
The plasmid pET-16b-VP2 (Noteborn et al., dates not publ;~h~) contains CAV DNA sequences of positions 380 to 1512. This CAV DNA fragment contains the coding region for VP2 flanked by 484 bp 3'-non-coding CAV DNA sequences. 106 bp downstream of the start codon for VP2 the start codon for VP3 is found in another reading frame. The plasmid pET-16b-VP2 was treated with the restriction enzymes NdeI
and NheI, and the sticky ellds were filled by means of Klenow polymerase. A 0.8 kb CAV DNA fragment was isolated.
The plasmid pAcUW51 was linearized with BamH1, the sticky ends filled by means of Klenow polymerase and finally treated with alkaline phosphatase ~CIP). The 0.8 kB CAV
DNA fragment was ligated at the linearized pAcUW51 DNA.
The orientation of VP2 in pAcUW51 was determined by restriction enzyme analysis. This construct was called pUW-VP2.
The pl~-cm;~ pET-16b-VP1 (Noteborn et al., data not publ;qhe~) contains CAV DN~ sequences of positions 853 to 2319. The CAV DNA insertion contains the complete coding region for the protein VPl flanked by 117 bp 3'-non-coding CAV DNA sequences. The plasmid pET-16b-VPl was treated with the restriction enzymes NdeI and EcoRI, and the sticky ends were filled by means of Klenow polymerase. A
1.45 kb CAV DNA fragment was isolated. The plasmid pUW-VP2 was linearized by EcoRI, the sticky ends filled by means of Klenow polymerase and finally treated by CIP. The 1.45 kb CAV DNA fragment was ligated at the linearized pUW-VP2.
The orientation of VP1 opposite of the plO promoter unit was determined by restriction-enzyme analysis, and the final construct pAcVPl/VP2 is shown in Figure 3.
Construction of rec~mhin~nt-VPl/VP2 baclllovirus.
The open reading frames encoding VPl and VP2 were separately cloned into a single baculovirus transfervector, viz pAcUW51. The CAV sequences encoding VPl are under the regulation of the baculovirus plO
promoter and VP2 under the regulation of the baculovirus CA 0222l~70 l997-l2-0~
wos6/40s31 PCT~L96/00230 poyhedrin promoter. Transfection of Sf9 insect cells occurred with 'naked' baculovirus DNA and transfervector DNA. After homologous recombinantion baculovirues were obtained which had incorporated the VP1/VP2 expression unit, integrated in the polyhedrin region of the recombinant baculovirus, instead of the lacZ unit. The recombinant baculoviruses were characterized for the absence of beta-galactosidase activity and integration of CAV DNA sequences.
Expression of the CAV prote; n~ VP1 and VP2 ; n Sf9 c~lls.
The simultaneous expression of the CAV proteins VP1 and VP2 in Sf9 cells infected with recombinant-VP1/VP2 baculovirus was analyzed by Coomassie-brilliant blue staining and protein labeling with Promix (ICN, USA) or 3H-leucine (Amersham, UK) and PAA-SDS gel electrophoresis.
In the PCT/NL94/00168 it was shown that lysates of insect cells infected with recombi nant-VP1 baculovirus contained a CAV-specific protein of 52 kD and expression of VP2 by recombinant-VP2 baculovirus in infected insect cells produced a major specific product of 30 kDa.
Infection of insect cells with recombinant-VP1/VP2 baculovirus resulted in the synthesis of both the CAV-specific proteins of 52 kD and 30 kD. Both CAV-specific products could be detected as radioactively labeled protein band or Coomassie-brilliant blue stained protein band. The latter result indicates that both products are produced in relatively high levels in recombi nant-VPl/VP2-baculovirus-infected insect cells. Sf9 cells infected with a recombinant-lacZ baculovirus did not contain these CAV-specific proteins.
Thus we have obtained evid~nce that inoculation in hens of crude lysates of recombinant-VP1/VP2-infected Sf9 - 35 cells are able to induce neutralizing antibodies directed against CAV.
CA 0222l~70 l997-l2-0~
Wo 96/40931 PCT/NL96/00230 The role OI' VP2 for the formation of a conformational neutr~lizing epitope of VPl.
As reported in PCT/NL94/00168 and by Koch et al.
(1995), simultaneous synthesis and not simply mixing of 5 recombinant CAV proteins VPl and VP2 is required to obtain a neutralizing and protective immune response. These data suggest that VP2 is a non-structural protein that at some stage of infection is required for virus assembly and/or the correct conformation of VP1, which result(s) in the 10 formation of the neutralizing epitope(s). One explanation of the requirement of VP2 might be that it acts ~s a scaffold protein that is necessary during the assembly of the virion but absent in the final product (Leibowitz and Horwitz, 1975). Examples of scaffold proteins are the IVa2 15 and 39kDa proteins of adenovirus (D'Halluin et al., 1978;
Persson et al., 1979). These proteins act as scaffolds for the formation of the so-called light capsid, but are L~..oved in the next step. VP2 might function in a s;m;1;~r way during the formation of CAV virions. However, at this 20 stage, we cannot entirely exclude that (very) small amounts of VP2 that remained undetected in electroblots of purified CAV preparations (Todd et al., 1990) or in electron microscopic photographs of lysed CAV particles incubated with immunogold-labeled VP2-specific monoclonal 25 antibodies, as described above, associate with VP1 and form conformational neutralizing epitopes. Recently, weak evidence for the presence of VP2 in gradient-purified CAV
was reported (Buchholz, 1994).
In the following experiments, evidence is provided 30 that the neutralizing epitope of VP1 is only (optimal) present, when VP2 is simultaneously synthesized. Insect cells were infected with recombinant-CAV baculoviruses expressing VP1, VP2 (see PCT/NL94/00168) or both VP1 plus VP2. The infected Sf9 cells were harvested 3 or 4 days 35 after infection and used for immunofluorescence tests with the CAV-specific neutralizing monoclonal antibody 132.1.
The cells containing only the CAV-specific protein VP2 did CA 0222l~70 l997-l2-0~
WO96140931 PCT~L96/00230 not react at all with the monoclonal antibody 132.1. Cells cont~;n; ng only VPl revealed a very poor immunofluorescence signal after incubation with monoclonal antibody 132.1. However, insect cells infected with recombinant-VP1/VP2 baculovirus expressing both VP1 and VP2 bound very strongly to the neutralising monoclonal 132.1. PAA-SDS gel electrophoresis of in parallel radioactive-labeled lysates of insect cells expressing VP1, VP2 or VP1 plus VP2, revealed that VP1 is expressed at the same level when expressed only or simultaneously with VP2.
VP1 and VP2 interact temporarily with each other.
The neutralizing epitope of VP1 is only formed when VP2 is present, and therefore is a conformationally distinct epitope. This implies that VP1 and VP2 associate with each other during a short time period. By means of ;mmllnoprecipitations under very mild conditions, we have ~m; ned whether VP1 could associate with VP2. Sf9 insect cells were infected with recombinant baculoviruses, which synthesized VP1, VP2, or VP1 plus VP2.
The results clearly reveal that monoclonal antibody 111.1 precipates VP2 when VP2 is synthesized alone or in the presence of VP1. In the case that besides VP2, VP1 was expres sed also, VP1 co-precipitated to a small extent with VP2. The monoclonal antibody 111.1 did not detectably precipitate VP1, when VP1 was synthesized in the absence of VP2. These data indicate that VP1 and VP2 are (to a relatively small amount) associated to each other. During this association event, VP1 might obtain its conformation resulting in the neutralizing epitope.
Basis for the development of vaccines aaa;nst CAV
infections The above presented results show that for the induction of neutralizing antibodies against CAV, VP1 is required which has a specific conformation. In a CA 02221~70 1997-12-0~
baculovirus expression system, this correct VP1 conformation is only possible, when VP1 plus VP2 or VPl plUS VP2 plus VP3 are simultaneously synthesized.
Denaturation of VP1 with e.g. sodium-dodecyl-sulphate result also in the destruction of it neutralizing epitope, indicating that the VPl neutralizing epitope is an conformational one.
The recombinant CAV products, VP1 plus VP2 or VP1 plus VP2 plus VP3, which will be used for vaccination of laying-hens, can be synthesized by means of the baculovirus system. The CAV proteins can also be synthesized by means of other expression systems, such as yeast cells, via (retro)- viral infection or gene amplification (CHO-dhfr system) in m~mm~l ian cell systems.
In principle, the expression of fragments of VP1 (in combination with VP2 or VP2 and VP3) may be sufficient for the induction of a protective immune response. The fact that 12-mers of VP1 can not react with neutralizing antibodies against CAV indicates that larger VPl fragments 20 are needed for getting the correct VPl conformation to form the neutralizing epitope. However, one should take into account that minor amino-acid mutations or a few amino-acid deletions might not influence the formation of the neutralizing epitope of VPl.
The fact that 2 or 3 proteins encoded by the CAV open reading frames can induce a protective immune respons is also applicable to the development of living virus vectors. The coding sequences for VPl plus VP2 or VPl plus VP2 plus VP3 are then cloned into living virus vectors.
It is also possible that one of the CAV proteins, VPl, VP2 or VP3, separately, but then within the context of a living virus vector, is also suitable for the induction of a protective immune response against CAV
infections. The expression of fragments of one of the abo ve-mentioned CAV proteins by living virus vectors may be sufficient for the induction of a protective immune response.
CA 0222l~70 l997-l2-0~
WO96/40931 PCT~L96/00230 The fact that VP3 causes apoptosis in, i.e. chicken mononuclear cells (PCT/NL94/00168i Noteborn et al., 1994a favors to construct living virus vectors not expres sing VP3. The replication of i.e. Marek_s disease virus might be negatively influenced by VP3-induced apoptosis.
Alternatively, one can produce attenuated CAV
expressing VP1 with the required conformation needed for eliciting a neutralizing and protective immune response agnaist CAV infections.
Co~truction of a rec~mh;n~nt-~nV-VP1/VP2 trAncfçr vector.
The coding sequences for the CAV proteins VP1 and VP2 were cloned into the Marek's disease virus (MDV) transfervector pMD-US10-SV (Koch, unpublished data). The transfervector contains the SV40 early promoter, which are flanked by sequences of the MDV US10 region, and prokaryotic sequences for multiplication in bacteria.
A schematic representa tion of the transfer vector is given in Figure 4.
The CAV coding sequences from position nt 368 to nt 2319 were inserted in the pMD-US10-SV transfervector under the regulation of the Sv40 ealy promoter. This recombinant transfervector was checked by restriction enzyme digestion and is called pMD-US10-SV-VP1/VP2.
By introducing a point-mutation at position 549 {T
was changed into an A) an extra stopcodon has been introduced in the gene encoding VP3 (Noteborn, unpublished data). Therefore, the inserted CAV sequences will only express VP1 and vP2. Indirect-immunofluorescence analysis of chicken embryo fibroblasts (CEF) transfected with the vector pMD-US10-SV-VP1/VP2 proved that VP1 and VP2 were indeed expressed, whereas VP3 was not.
Construction of rec~mhin~nt-VP1/VP2 ~nv.
Using the Ca-phosphate transfection method, recombinant transfer vector pMD-US10-SV-VP1/VP2 DNA was transfected with MDV (Rispens isolate) DNA,in CEF cells.
CA 0222l~70 l997-l2-0~
WO96/40931 PCT~L96/00230 After homologous recombination, recombinant MDVs were obtained, which had incor porated the CAV coding sequences in the the USlO region ~Nakamura et al., 1992). The recombinant-VPl/VP2 MDVs were characterized for the presence of the expression of VP2. By in-parallel plaque purification and ;mmllno-peroxidase analyis using a monoclonal antibody directed against VP2, several 100%-purified recombinant-VPl~VP2 MDV independent strains were obtained.
Char~cter;~at;on of recnmhin~nt-VPl~VP2 ~nv.
The correct integration of the CAV-DNA sequences in the MDV genome was determined by means of PCR and restriction-enzyme analysis. By subsequent passaging of the various purified recombinant-VPl/VP2 MDVs, it was shown that they remained stable. No recombinants were obtained with (partial) loss of the VPl/VP2 expresssion unit.
The simultaneous expression of the CAV proteins VPl and VP2 in CEF cells, which were infected with the recombinant-VPl/VP2 MDV, was proven by indirect immunofluorescence. The monoclonal antibodies CVI-CAV-111.1 (111.1), directed against VP2 and CVI-CAV-132.1 (132.1), directed against VP1 were used.
The monoclonal antibody 132.1 is directed against a neutralizing epitope of VP1. The fact that the neutralizing antibody 132.1 can recognize recombinant-MDV
expressed VP1, co-synthesized with VP2, implies that the required neutralizing epitope is present on MDV-expressed VP1. Therefore, vaccination of chickens with recombinant-VP1/VP2 MDV will result in the induction of a neutralizing/protective antibody response. Besides the synthesis of the CAV VP1 and VP2 proteins, the recombinant-VP1/VP2 MDV will synthesize the MDV proteins required for the induction of a protective immune response against MDV infections.
CA 02221~70 1997-12-0~
WO 96/40931 . PCT/NL'~6/00'~0 Pro~uc~;on of attenuated CAV based on the cloned CAV
genome pCAV/EcoRI.
The CAV-EcoRI clone is used for the production of ~ viable infectious CAV particles. To that end, the complete CAV insert, the 2,319-bp EcoRI fragment has to be isolated from the bacterial sequences and recircularized by DNA
polymerase treatment. Subsequently, e.g. MDCC-MSB1 cells are transfected with the recircularized EcoRI fragments and after several days wild-type CAV will be produced.
One can introduce mutational changes in the CAV
sequences of the CAV-EcoRI clone and isolate, recircularize and transfect in MDCC-MSBl cells. Instead of wild-type CAV, in principle one can produce mutant CAV and if the mutant is less pathogenic, attenuated CAV. The complete strategy for the production of attenuated CAV is shown in Figure 5.
Constrllct;o~ of CAV gen~mes co~tA;ninq mlltate~
promoter/~nh~ncer reaions.
A remarkable feature of the CAV promoter/enhancer region is a sequence of 4 or 5 near-perfect 21-bp repeats, interrupted by an insert of 12-bp (Noteborn et al., 1991).
This region is involved in the regulation of the CAV
transcription (Noteborn et al., 1994b).
For the production of attenuated CAV, we have introduced mutational changes in the 12-bp insert/direct-repeat region of the CAV-EcoR1 clone (Noteborn et al., 1991). The mutated promoter/enhancer region of the wild-type (wt) and the various CAV mutants are shown in Fig. 6. The Nae-mutant contains no 12-bp/direct-repeat region sequences at all. Tnstead of these, a NaeI site (5'-GCCGGC-3') has been introduced, which is given as 'N' in figure 6.
All other mutants contain 4 original direct repeats instead of 5, as is the case for the CAV-EcoRI clone. The various CAV mutants, called '6b'p, '12bp', '24bp' contain changed 12-bp inserts. The mutant 'wt in Nae' and of CA 02221~70 1997-12-0~
WO96/40931 PCT~L96/00230 course the original CAV-EcoRI clone, called 'wt', contain the original 12-bp insert sequences 5'-AAGAGGCGTTCC-3'.
The CAV mutants '6bp', '12bp', '18bp', '24bp' and 'wt in Nae' contain all additional sequences flanking the 12-bp insert/direct-repeat region. At the 5'-site of this region, the linker 5'-GCCCATGT-3', and at the 3'-site the linker 5'-GATCCGCC-3' has ~een introduced.
Mtltate~ CAV a~nomes resl~lts in the production of attenuated infectious CAV.
To detPrmine whether the mutated CAV genomes could produce live CAV particles, firstly the synthesis of VP3 was ~mined. At several timepoints after transfection, a part of the various transfected MDCC-MSBl-cell cultures were aceton-fixed and analysed by indirect immllnofluorescence using a monoclonal antibody directed against VP3. In parallel, 1 ml of each culture was added to 9 ml of fresh RPMI-medium, which was supplemented with 10~ fetal bovine serum.
Approximately 15% and 90% of the cultured MDCC-MSB1 cells, transfected with 'wt' recircularized CAV genome DNA, contained VP3 after 6 days and 11 days (the cells were one time passaged after transfection), respectively.
The CAV mutant genome 'Nae', lacking the complete 12-bp insert/direct-repeat region, was shown not to produce infectious virus particles. Six days after transfection, at most 2~ of the cells produced VP3, which is due to transient expression of the 'Nae' DNA. A simil~r percentage is obtained with expression plasmid pRSV-VP3 30 (Noteborn et al., 1994b) encoding VP3 only, and which are known not to replicate in eukaryotic cells. After 3 weeks and several passages, no VP3 was present anymore in the Nae-DNA transfected MDCC-MSB1 cell cultures.
At various time-intervals after transfection, the percentage of VP3-positive cells of the MDCC-MSB1 cultures, transfected with the mutant-DNA genomes '6bp', 12bp', 18bp, 24bp and 'wt in Nae' was significantly lower CA 0222l~70 l997-l2-0~
WO96/40931 PCT~L96/00230 compared with cultures, transfected with 'wt'-DNA genome.
These data imply that the various CAV mutants replicate less fast than the wild-type CAV. Especially, the mutants '6bp' and '18bp' were reduced in their replication rate.
Most likely, the mutational changes of the 12-bp insert results in the lower virus spead of the mutated CAV. The results of these experiments are shown in Figure 7.
Subsequently, we have infected fresh MDCC-MSB1 cultures with supernatants of cells tran~fected with all 10 ~mi ned mutated CAV-DNA genomes. All supernatants, except the one derived from 'Nae'-DNA-transfected cells~ were proven to contain infectious virus parti cles. For these cultures, infected with the 'mutated-virus' containing supernatants, it could be shown by indirect immunofluorescence, that cells were present containing VP3.
CAV mllt~nts h~ve ~ re~uce~ cvtopa~hoq~n;c effect.
In parallel with the above described detection of VP3 synthesis, the transfected cells wçre analysed whether they had become apoptotic. CAV is known to induce apoptosis, 2-3 days after infection. To that end, the cells were stained with propidium iodide, which stains 'normal' DNA strongly, but apoptotic DNA weakly and/or irregularly. Already, 11 days after transfection almost all MDCC-MSB1 cells transfected with 'wt' DNA were shown to be apoptotic, whereas the majority of the cells, transfected with the various mutated CAV-DNA genome were not. The capacity for inducing apoptosis was shown to be mostly reduced for the CAV mutants '6bp' and '18bp'.
DNA ~lys;~ of att~nl~ted CAV.
By polymerase-chain reaction and sequence analysis of the 12-bp insert/direct-repeat region and flanking sequences, it was shown that the original mutations were not changed for the various CAV mutants '6bp', '12bp', '18bp', '24bp' and 'wt in Nae'. These results indicate CA 02221~70 1997-12-0~
wos6/4o93l PCT~L96/00230 that the various CAV mutants are stable, at least after culturing in MDCC-MSBl for about l month and that indeed these CAV mutants are viable and causing a reduced cytopathogenic effect in cultured chicken T cells.
Southern blot analysis of DNA isolated from MDCC-MSBl cultures, infected with the various CAV mutants, revealed that all viable CAV mutants produced all CAV DNAs, as was described for wild-type CA~. The double-stranded replication intermediate and sing le-stranded DNA were detected for both wild-type as mutated CAV.
Attenuated CAV synthesizes the CAV-specific neutral;zin~
epitope By indirect-immunofluorescence, using the neutralizing monoclonal antibody CVI-CAV 132.l and a monoclonal antibody directed against VP2, viz CVI-CAV
lll.2 and VP3, viz CVI-CAV-85.l, it was shown that all mutated CAV g~nnm~S were able to synthesize the CAV
proteins VPl, VP2 and VP3. Even more important is that the neutralizing monoclo nal antibody 132.l reacted with cells, infected with the various CAV mutants. This finding indicates that the mutated CAVs will produce the required neutralizing CAV-specific epitope, whcih has to be recognized by the immune system of vaccinated chickens as CAV for eliciting a protecvctive immune response.
It can be concluded that based on the CAV clone pCAV-EcoRI, mutated CAV genomes can be made, resulting in the production of viable mutated CAV particles. These CAV
mutants replicate in cultured chicken T cells less fast than wild-type CAV. The cytopa thogenic effect caused by these CAV mutants is also reduced compared to wild-type CAV. The CAV mutants are all able to produce all CAV
proteins resulting in the required neutrali zing epitope on VPl.
Therefore, these CAV mutants are attenuated versions of CAV in the field.
CA 02221~70 1997-12-0~
Description of the Figllres Figure 1 shows the pepscan analysis of the neutralizing monoclonal antibodies of type 132.1 with - peptides (12-mers~ derived from VP1.
Figure 2 shows the pepscan analysis of the - neutralizing monoclonal antibodies of type 132.1 with peptides (12-mers) derived from VP2.
Figure 3 shows the diagrammatic representation of the recombinant transfer pUW-VP1/VP2.
Figure 4 shows the diagrammatic representation of the recombinant transfer vector pMD-US10-SV-VP1/VP2., Figure 5 shows the strategy for the production of attenuated CA~-mutants, based on the plasmid pCAV/EcoR1 containing 2319 bp of wild-type CAV.
Figure 6 shows the schematic structure of the CAV
promoter/enhancer region of the various mutated and wild-type CAV strains.
Figure 7 shows the VP3-expression rates obtained for the various mutant-CAVs and wild-type CAV after tranfection of mutant or wild-type circularized DNA. The VP3-expression rate are given as percentage of VP3-positive MDCC-MSB1 cells.
Figure 8 gives the sequence of CAV.
CA 0222l~70 l997-l2-0~
WO96/40s31 PCT~L96/00230 REFE~N~
1. Boyle, D.B. and Heine, H.G. 1993. Recombinant fowl pox virus vaccines for poultry. Immunology and Cell Biology 71, 391-397.
BRIEF DESCRIPTION OF T~ lNv~NllON
The present invention provides the formation and characterization of the ..~Ll-li~;ng conforma~;~Al epitope of the CAV protein VPl, which is required for eliciting a protective Lmmune ~e~u~l~e in vA~c;nAted animals.
In par~ l1 Ar, the production of ll~uL~ ;ng an~; h~; ~5 againt CAV is descr; h~ . In a diagnostic test, based on these produced neutrAl;~;ng ant;ho~;~s, CAV
(part;~l~s) are detected.
Various vA~c;n~ ve~Lo~ A;nct CAV infections are ~;cclnsed~ All these vACc;n~c are less pa~h~en;~ than CAV. All these vA~;n~ vector are shown to ~ u~e the required neutr~ ;n~ confol~t;onAl epitope of CAV.
One vector provides a subunit vA~c;n~, based on a recombinant baculovirus expressing both VPl and VP2 in the same cell. A second type of vA~c;n~ is a live virus vector, comprising a Marek's disease vector stably h~rhoring the coA;ng se~n~c for VPl and VP2. The third CAV vA~C;ne comprises genet;~lly attenuated CAV str~;ns with a reduced cytopathogenic effect.
BACRGROUND OF THE lNv~NllON
Chicken An- ~A virus (CAV) is a sm~ll virus of a unique type with a particle diameter of 23 to 25 nm and a genome consisting of a circular c; n~l e-stranded (m;nus-strand) DNA (Gelder blom et al., 1989, No~hnrn et al., 1991 and Todd et ~l., 1990). This DNA mult.;rl;~5 in infected cells via a circular ~ hle-stranded replicative intermediate, which was L~l.Lly clon~ and fully se~-~n~e~. The CAV genome is 2319 nucleotides long (Not~h~rn and De Boer, 1990). DNA analysis of CAV strains isolated in different continents revealed only m;nor 5UBSTITUTE SHEET (RULE 26) CA 02221j70 1997-12-Oj differences among the various isolates (Meehan et al., 1992; accession number M81223, Claessens et al., 1991;
D10068, Kato et al., 1995; D31965 and Pallister et al., 1994 Soine et al. 1993 and 1994; L14767). Recently, on the basis of the genome structure, CAV has been placed into the novel virus family of Circoviridae. However, CAV is not related to the other members of this virus family consisting of ~n;m~l single-stranded circular-DNA viruses, such as porcine circovirus and psittacine beak-and-feather-disease virus (Noteborn and Koch, 1995).
The CAV genome contains one evident promoter/enhancer region (Noteborn et al. 1994) which regulates the CAV
transcription. The major transcript from the CAV genome is an unspliced polycistronic mRNA of about 2100 nucleotides encoding three proteins of 51.6 kDa (VPl~, 24.0 kDa (VP2) and 13.3 kDa (VP3 or apoptin (Noteborn and Koch, 1995, Noteborn et al., 1992 and Phenix et al., 1994). All three predicted CAV proteins are synthesi zed in CAV-infected cells (Noteborn and Koch, 1995). Tmmlln;zation with (recombinant) VPl and VP2 synchronously synthesized in the same cells elicits a protective response and can be used as subunit vaccine against chicken infectious anemia (Koch et al., 1995 and Noteborn and Koch, 1994c).
CAV causes clinical and subclinical disease in chickens, and is recognized as an important avian pathogen worldwide (McIlroy et al., 1992 and McNulty et al., 1991).
Day-old chicks are especially susceptible to CAV
infections. In these ~n;m~l S lethargy, anorexia and anemia are observed from 10 days after inoculation with CAV.
After infection mortality may increase to a m~; mllm of 50%. With increasing age the resistance also increases (Jeurissen et al., 1992). The hematocrit values of chicks that had been infected with CAV at an age of 1-3 days are decreased. CAV infections of 1-21 days old chicks result in a depletion of in partlcular the thymus cortex.
However, in older chickens CAV can subclinically multiply.
CA 0222l~70 l997-l2-0~
WO96/40931 PCT~L96/00230 CAV infection in older-chickens can be determined by the occurence of seroconversion.
The depletion of the cortical thymocytes is considered to cause immunodeficiency resulting in enhanced concurrent infections and to vaccination failures (Noteborn and Koch, 1995). The depletion of thymocytes and most likely also of erythroblatoid cells occur via CAV-induced apoptosis (Jeurissen et al., 1992a). The CAV-encoded protein apoptin is the main inducer of this phenomenon (Noteborn et al., 1994).
Maternal antibodies have been found to give an important protection against CAV infection. Vielitz et al.
(1991) reported that hens exposed to CAV from large amounts of antibodies, which are passively transferred to the offspring per ovum. These antibodies protect against chicken infectious-anaemia-associated disease.
CAV-neutralizing antibodies were detected in yolk of eggs produced by hens that had been inoculated with lysates of cells that had been co-infected with CAV-recombinant baculovirus and produced all three CAV proteins, or mainly VP1 and VP2. Specific clinical signs did not develop in CAV-challenged progeny that hatched from these eggs (Koch et al., 1995).
Vielitz and Landgraf (1988) have developed a vaccine against infectious anaemia, which is based on CAV
propagated in chicken embryos. Currently, this is the only commercially available vaccine. The offspring of vaccinated breeders are protected againt infectious anaemia. Vaccination is possible because when maternal immunity vanished, the birds are susceptible to virus infection without developing the disease. Obviously, the use of live vaccines based on non-attenuated virus harbors risks. Experimental infection of 3-week-old chickens resulted in a comprehensive decrease of the functions of the immune system (McConnell et al., 1993, and 1993a) in the absence of disease. In line with this finding, McIlroy (1992) have provided evidence that CAV also causes CA 0222l~70 l997-l2-0~
WO96/40931 PCT~L96/00230 considerable economic losses in the absence of disease:
the subclinical disease negatively affected feed conversion and average body weight and increased medication, both of which result in a considerable financial burden. So far, non-pathogenic CAV has not been isolated.
The recombinant CAV proteins synthesized by means of the baculovirus expression system can be used as a subunit vaccine. The recombinant CAV proteins VPI and VP2 have been proven to protect chicks by maternal immlln-ty (Koch et al, 1995). Since the baculovirus vector is an insect-specific virus, known to be non-pathogenic for vertebrates, it can be cultured and supplied to chicken without undue risks ~Vlak and Keus, 1990).
In general, live-virus vaccines induce a better immune response and are less expensive than sub-unit vaccines. Therefore, knowledge about the immunogenicity of the various CAV proteins can be used to construct attenuated CAV or other recombinant-virus vectors, such as avian herpes viruses (Nakamura et al., 1992, Morgan et al., 1993) or fowlpox virus (Nazerian et al., 1992, Boyle and Heine, 1993). These recombinant viruses should express the CAV protein VPl and VP2, in addition to their own proteins, and may be applicable as vaccine for both layer breeders and broiler breeders to protect their offspring against infectious anaemia. In addition, such vectors may be used to protect maternally immune broilers against subclinical disease.
DETAILED DESCRIPTION OF THE INVENTION.
The present invention relates to production and analyses of the neutralizing conformational epitope structure of chicken anemia virus (CAV).
Furthermore, the production of neutralizing monoclonal antibodies directed against CAV is disclosed.
It is shown that these neutralizing antibodies are CA 02221~70 1997-12-o~
WO96/40931 PCT~L96/00230 directed against a conformational epitope of CAV protein VPl.
Also a diagnostic test kit, based on these neutralizing antibodies, for the detection of CAV will be described. This invention provides evidence for the me~h~nism by which the neutralizing antibodies neutralize CAV particles.
For the formation of the neutralizing conformational epitope of VPl, the synthesis of VP2 within the same cell is required. Recombinant baculovirus expressing only VPl in insect cells only does not react with neutralizing antibodies directed against CAV, but these neutralizing antibodies will react when VPl and VP2 are synthesized in one cell.
In purified CAV capsids, however, only VPl is present. This invention discloses that during the synthesis of VPl, and most likely during its complex formation resulting in the CAV capsids, VP2 binds temporarily to VPl. Denaturation of the CAV capsids results in the destruction of the neutralizing epitope, indicating that the neutralizing epitope is an conformational one.
Besides, the invention relates to vaccines and compositions for preventing or treating virus infections in poultry, in particular infections with CAV.
In particular, the invention relates to vaccines that are less pathogenic than the CAV itself but are still capable of producing the neutralizing conformational epitope. Vaccination of chickens with these type of vaccines will lead to the generation of neutralizing antibodies and thus protect the ~ n; m~ and their progeny against CAV infections.
The invention relates to a baculovirus vector which contains separately on its genome the coding sequences for VPl or VP2. This recombinant baculovirus is able to synthesize VPl and VP2 in the same cell, resulting in the CA 0222l~70 l997-l2-0~
W096/40931 PCT~L96/00230 formation of the neutralizing conformational epitope of CAV.
The invention also relates to the construction of a Marek's~disease virus (MDV) vectors cont~in;ng CAV
sequences encoding VP1, VP2 proteins. In particular, this recombinant MDV vector synthesizes the recombinant CAV
proteins in such a way that the neutralizing conformational epitope of VP1 is properly made.
Furth~rmnre, the invention describes the formation of various attenuated CAV strains, which reveals a reduced cytopathogenic effect in chicken T cells in comparison to a a wild-type-derived CAV strain. The attenuated CAV
strains were made by introducing point mutations in a cloned CAV DNA genome, in particular a sequence within the promoter/enhancer region has been mutated. The attenuated CAV mutant strains are able to produce the neutralizing conformational epitope.
Processes for the prophylaxis or control of CAV
infections, in particular in chickens, and processes for the preparation of recombinant parts of CAV comprising sequences, and processes for the preparation of vaccine are also subjects of the invention.
Thus, reiterating the invention provides a neutralizing antibody or an antibody fragment or derivative thereof reacting with a conformational epitope of viral protein 1 (VP1) of chicken anaemia virus (CAV) recognized by a monoclonal antibody designated as 132-1, 132-2 or 132-3, as produced by the hybridoma's deposited under no.'s xxxxxx, yyyyyy, zzzzzz at the Insitut Pasteur, Paris, France. A workable experiment for det~rmining whether an antibody is an antibody according to the invention is to see if it cross-reacts (or competes) with an antibody from the deposited hybridomas. Fragments and derivatives of antibodies are well known in the art and hardly need further explanation for the person skilled in the art.
CA 02221~70 1997-12-0~
The invention also provides a conformational neutralizing epitope of viral protein 1 of chicken anaemia virus recognized by an antibody as disclosed above. The epitope may be part of a larger molecule, it may for 5 instance be bound to a carrier or the epitope may be & repeated (at intervals) in a polypeptide chain. Preferably the epitope is part of a larger part of VPl, because such a molecule will have the right conformation more easily.
As described the conformational epitope will only be 10 present on VPl if it is produced in one cell, preferably from one vector together with VP2. Therefore the.invention provides a method for producing a viral protein 1 comprising a conformational epitope as disclosed a~ove, comprising the expression of said viral protein 1 in one 15 cell together with viral protein 2 of said CAV whereby the genetic information encoding VP1 and the genetic information encoding VP2 are separately present on one recombinant vector.
The invention also includes vectors for use in a 20 method just described comprising as two separate coding sequences the genetic information encoding VP1 and the genetic information encoding VP2. Preferably such a vector is based on Marek's disease virus vector so that a vaccine can be produced giving protection against two pathogens.
A very safe and efficient expression system for the viral proteins according to the invention are vectors which are based on a baculo virus vector. As explained before Baculovirus is generally regarded as safe for use in vertebrates since it cannot infect them.
The invention also provides another way of arriving at vaccines or vaccine components which do have the very important neutralizing comformational epitope, but have reduced pathogenicity. (Attenuated viruses for instance.) This is achieved by providing a method for providing a viral protein 1 comprising a neutralizing conformational epitope according to the invention, comprising expressing at least a functional part of VP1 and VP2 from genes CA 0222l~70 l997-l2-0~
WO96/40931 PCT~L96/00230 encoding them, at least one of which genes is under control of a regulatory sequence derived from the CAV
sequence upstream of the transcription intitiation site which regulatory sequence is modified to reduce its efficiency. In this way recomnbinant viruses can be produced which do not replicate as fast and therefor are less pathogenic ~i.e. attenuated).
Such virus particles are also part of the invention.
As disclosed hereinbefore the modification is preferably in the promoter/enhancer region and most preferably the modification is in the 12 base pair insert in the promoter enhancer region.
Recombinant virus particles obtainable by any method according to the invention are also part of the invention, as are nucleic acids for use in any method according to the invention, for instance vectors comprising a gene encoding at least a functional part of VPl and a gene encoding a functional part of VP2, at least one of the genes being inder control of a regulatory sequence which is modified to reduce its efficiency.
The antibodies and epitopes according to the invention are also useful in a diagnostic test kit for detecting or det~rmining the presence of CAV or antibodies to CAV in a sample Furthermore vaccines for the treatment or prophylaxis of CAV associated disease comprising an antibody or an epitope according to the invention together with a suitable adjuvans and/or a suitable vehicle for administration are also provided herewith as are vaccines for the treatment or prophylaxis of CAV associated disease comprising recombinant virus particles according to the invention together with a suitable adjuvans and/or a suitable vehicle for a~min;ctration.
The invention will be explained in more detail on the basis of the following experimental part. This is only for the purpose of illustration and should not be lnterpreted as a limitation of the scope of protection.
CA 0222l~70 l997-l2-0~
W096/40931 PCT~L96/00230 EXPERIMENTAL
Purification of CAV particles to elicit neut~alizing mo~oclonal antiho~ies aga;n.~t CAV
For the production of neutralizing monoclonal antibodies against CAV, mice were injected with purified CAV particles.
The supernatant of a 1-liter culture of CAV-infected MDCC-MSB1 cells was fourty times concent~ated by means of a MILLITAN 300-kDa filter (Millipore, USA). The supernatant was dialyzed against lOmM Tris(ph 8.7)-lmM
EDTA (TE) buffer. Subsequently, sodium dodecyl sulphate (SDS) to an end-concentration of 0.5% was added to the CAV-capsid suspension and incubated for 30 minutes at 37 C. Finally, the CAV capsids were pelleted on a 30%
sucrose cushion. The pellet cont~;n;ng the CAV capsids was resuspended in 1 ml TE buffer. Mice were twice injected with 100 ~ul CAV-capsid suspension.
In-vitro neutralization test.
The supernatants of the candidate monoclonal antibodies were diluted 1:2 and then a two-fold dilution series was made. The diluted supernatants were incubated for 1 hour with 104-105 TCID50 CAV-Cux-1 (Von Bulow et al., 1983, Von Bulow, 1985). Approximately one hundred thousand cells of the T cell line MDCC-MSB1 transformed by Marek's disease virus were infected with this mixture of diluted supernatant and virus (Yuasa, 1983, Yuasa et al.
1983).
Tmmllnofluorescence and immunoperoxidase assay Cells were fixed with 80~ acetone and used for immunofluorescence assays with CAV-specific monoclonal antibodies and goat anti-mouse IgC conjugated with fluorescein, as decribed by Noteborn et al. (1990).
CA 0222l~70 l997-l2-0~
WO96/40931 PCT~L~6,0~230 Recombinant-Vpl/VP2-MDV-infected CEF were used for immunoperoxidase stai ning with CAV-pecific monoclonal antibodies, as described by Jeurissen et al. (1988).
5 EnzymP-l;nked ;mml~nosorh~n~ assay f~TISA~
Microtiter wells (Greiner~ FRG) were coated with the CAV-specific neutralizing monoclonal antibody 132.1, which was 1:10,000 diluted in 50 mM sodiumbicarbonate pH 9.6.
Wash the wells three times with tapped water cont~;n;ng 0.05% Tween 80. Saturate the wells with 100 ~ul phosphate-buffered saline cont~;n;ng 4% horse serum, 51 gram/liter NaCl, and 0.05% Tween 80 (saturation buffer) for 30 minutes at 37 C. Wash the wells three times with tap water containing 0.05% Tween 80. Next, 50 u~l of non-diluted chicken serum and 50 ~ul of thirty times concentrated supernatant containing CAV particles, or 50 ~ul of a lysate of insect cells containing recombinant VP1 and VP2 proteins, were mixed, added per well and incubated for 1 hour at 37 C. Wash the wells three times with tap water containing 0.05% Tween 80. Add per well 100 u~l a 1:2000 fold dilution of a peroxidase-labeled rabbit an ti-mouse immunoglobulin G conjugate in saturation buffer.
Incubate for 1 hour at 37 C. Wash again three times with tap water containing 0.05% Tween 80. Add 100 ~1 of a standard solution of tetramethylbenzidine, sodiumacetate and hydrogenperoxidase to the wells and incubate for 10 minutes at room temperature. The reactlons are blocked with 10~ H2SO4. The various wells are ~m; ned at 450 nm, as standard.
Baculovirus ,~nd i~ect cells.
The recombinant baculovirus AcRP23-lacZ (Bishop, 1992) was obtained from Dr. R. Possee, NERC Institute of Virology, Oxford, England, and the genomic DNA was purified as described by Summers and Smith (1987).
Spodoptera frugiperda (Sf9) cell were obtained from the American Tissue Culture Collection (no. CRL 1711).
CA 0222l~70 l997-l2-0~
Baculovirus stocks were grown in confluent monolayers and suspension cultures in TC-100 medium (GIBCO/BRL) containing 10% fetal calf serum, as described by Summers and Smith (19~7).
Clon; nq of CAV DNA.
All CAV DNA sequences are originally derived from the plasmid DNA pIc-20H/CAV-EcoRI (Noteborn and De Boer, 1990). All cloning steps with plasmid DNA were in principle carried out according to the methods described by Maniatis et al. (1982).
DNA transformations were carried out in the E.coli strain HB101. All plasmid were multiplied in large culture under agitation, purified on CsCl gradients, and then by filtration over Sephacryl-S500 columns or by filtrations on QIAGEN-chromatography columns.
Conctruct;on ~n~ 5~lect;0n of rec~mh;nAnt-VPl/VP2 bacl1lovirus.
Recombinant transfer vector pAcVP1/VP2 DNA was transfected with linearized recombinant baculovirus AcRP23-lacZ DNA, in Sf9 cells. After homologous recombinantion baculoviruses were obtained, which had incorporated in the polyhedrin unit instead of the lacZ
the two CAV proteins VP1 and VP2 under regulation of the promoter of the plO or polyhedrin gene, respectively. In first instance, the recombinant CAV viruses were characterized for the absence of beta-galactosidase activity in plaques of baculovirus-infected insect cells.
Further the integration of CAV DNA sequences in the baculovirus genome was det~r~;ned by means of a CAV-specific DNA probe in a hybridization experiment.
Immunoprecipitation assay Two days after infection, the cells were incubated with Promix label (ICN, USA~ and four hours later, the cells were lysed in ElA buffer (50 mM Tris (pH7.5), 0.1 CA 02221~70 1997-12-0~
WO96/40931 PCT~L96/00230 Triton-X-100, 250 mM NaCl, 50 mM NaF, and 5 mM EDTA) and incubated with monoclonal antibody 111.1 directed against VP2 for 2 hours at 4 C, washed with ElA buffer and separated on a PAA-SDS gel.
Tr~n~fection of ~nv DNA ;n ~s.
For the construction of recombinant-VP1/VP2 MDV, co-transfections with purified recombinant-VP1/VP2 MDV-transfervector and DNA, isolated from chicken embryo fibro blasts (CEF) infected with MDV Rispens isolate (van Vloten et al. 1972) were carried out according the method described by Graham and Van der Eb (1973).
~ansfection of chicken T cells with mutant-CAV ge~omes.
The various mutated-CAV clones were digested with EcoRI and the EcoRI fragmerlts cont~; n; ng the CAV (mutated) sequences was recircularized and transfected in MDCC-MSB1 cells, by using the DEAE-dextran method as has been described by Noteborn et al. (1991). As control, the whole procedure was in parallel carried out for the pCAV-EcoRI
clone.
RESULTS AND DISCUSSION
The production of neutralizing monoclonal antibodies against CAV.
Noteborn and Koch (1994) have described two types of CAV-specific monoclonal antibodies. One type is directed against VP2, while the other is directed against VP3. None of these monoclonal antibodies reveal a CAV-specific neutralizing activity. Even, more important was that none of these monoclonal antibodies was directed against VP1.
We assumed that a neutralizing monoclonal antibody might be directed against VPl, for the capsids contain mainly VPl (Todd et al., 1990). Below, we describe the production of neutralizing antibodies against CAV.
CA 0222l~70 l997-l2-0~
WO 96/40931 PCT/NL~)6/0~0 For the production of neutralizing monoclonal antibodies against CAV, mice were injected with purified CAV particles.
As a first screening for (neutralizing) monoclonal antibodies against CAV, microtitre wells were coated with recombinant-VP1/VP2-baculovirus infected insect cells, which co-synthesized both VP1 and VP2 (see below).
CAV-specific antisera with a high neutralizing titer reacted at a dilution of 1:1000 specifically with the recombinant VPl and/or VP2 products (see below). Several different hybridoma cell lines producing monoclonal antibodies, which specifically reacted with recombinant VP1/VP2 products, were obtained.
A CAV-specific serum neutralization test, showed that three of these monoclonal antibodies obtained, had a neutralizing activity against CAV. These three CAV-specific neutralizing monoclonal antibodies were called 132.li 132.2 and 132.3.(deposited under no's xxxx,yyyy,zzzz at the Institut Pasteur, France.
Microscopy examinations of the neutraliz;ng monoclonal antibodies d~ ected aga;n~t CAV.
Immunofluorescence showed that the three neutralizing monoclonal antibodies 132.1, 132.2 and 132.3 recognize specific structures in CAV-infected MDCC-MSBl cells. None of these monoclonal antibodies reacted with uninfected MDCC-MSB1 cells.
Electron-microscopic analysis was carried out with purified CAV particles incubated with neutralising antibodies against CAV (132.1) or with monoclonal antibodies 111.1 (against VP2) or 111.3 (against VP3).
Todd et al. (1990) have reported that purified CAV capsids contain onlya 50-kDa protein, which is most likely VPl.
The various monoclonal antibodies were detected by immunogold labeling. Only the neutralizing monoclonal antibodies 132.1 were found to bind to CAV particles.
Binding of the monoclonal antibody 132.1 to a CAV particle CA 0222l~70 l997-l2-0~
WO96/40931 PCT~L96/00230 resulted in its lysis. Furth~rmorer CAV capsids, which were lysed due to incubation with the neutralising monoclonal antibody 132.1, showed no binding with monoclonal antibo dies directed against VP2 or VP3.
These results reveal the mech~n; ~m by which the neutralizing monoclonal antibodies act: They cause the lysis of the virus capsids, by doing so causing non-infectious particles. Furthermore, these data show that purified CAV particles contain (almost) only VP1.
Neutr~l;z;ng ~noclon~l anl-;hodies are directed aaain~t an conformation~l epitope on VP1.
Pepscan analysis (Geysen et al., 1984) revealed that none of the 3 neutralizing monoclonal antibodies reacted significantly with one of the 12-mers derived from VP1 or VP2, or VP3. For the sake of brevity only the data obtained wwith monoclonal antibody 132.1 are shown for VPl in Figure 1, and for VP2 in Figure 2. These results indicate that the neutralizing monoclonal antibodies are directed against a conformational epitope.
These data were confirmed by the following experiments. Purified CAV particles, dotted on a nylon filter under native conditions, still could react with the neutralizing monoclo nal antibody 132.1. However, after boiling in the presence of SDS, the CAV capsid proteins did not bind to monoclonal antibody 132.1.
Immunoprecipitations experïments, carried under native conditions, as described by Noteborn et al.
(1994b), with partially purified CAV particles and monoclonal antibody 132.1, 132.2 or 132.3 showed that a protein of about 50 kDa was precipated by these monoclonal antibodies.
It can be concluded that the presented results indicate that the neutralizing monoclo nal antibodies are directed against an conformational epitope of VP1.
CA 02221~70 1997-12-0~
~nzyme-linked ;mm~lnosorbens assay (~TISA) based on 2 neutralizina antibody againct CAV.
We have developed a complex-trapping-blocking ~ ~CTB)-ELISA. One can use enriched CAV particles derived from CAV-infected MDCC-MSB-1 cells or recombinant VPl/VP2 proteins synthesized by means of the above described baculovirus system.
Serum from CAV-infected chickens contains antibodies which will block all epitopes on the CAV capsids.or recombinant VP1/VP2. This means that the CAV capsid or recombinant VPl/VP2 will not bind to the coated monoclonal antibody 132.1. Negative serum, howe ver, will allow binding of CAV capsids or recombinant VPl/VP2 to the coated 132.1. A signal smaller than 0.5 of the signal detected with a negative control serum will be ~m; ned as positive.
The detection level of our CTB-ELISA are titers of 24 to 25 a det~rm;ned in a serum neutralization test, which is very sensitive. More than 400 sera were analyzed.
Comparison to the serum neutralization test revealed that 96.5% of the positive sera within the serum neutrali zation test were positive within the CTB-ELISA, and 98.3%
of the negative sera within the serum neutralization test were negative within the CTB-ELISA.
Construction of a recom~;n~nt-VPl/VP2 transfer vector.
The coding sequences for the CAV proteins VPl and VP2 were cloned into the baculovirus transfer vector pAcUW51 (cat. no: 21205P), which was co~-rcially obtained from PharMingen, San Diego, USA. This vector is shown in Figure 3 and contains the polyhe drin flanking region, within their midst the baculovirus polyhdrin promoter and the plO
promo ter and for both transcription units, the required 3'-non-coding transcrioptional sequences including the polyadenylation signals. The transfer vector contains prokaryotic sequences for multiplication in bacteria.
CA 0222l~70 l997-l2-0~
The plasmid pET-16b-VP2 (Noteborn et al., dates not publ;~h~) contains CAV DNA sequences of positions 380 to 1512. This CAV DNA fragment contains the coding region for VP2 flanked by 484 bp 3'-non-coding CAV DNA sequences. 106 bp downstream of the start codon for VP2 the start codon for VP3 is found in another reading frame. The plasmid pET-16b-VP2 was treated with the restriction enzymes NdeI
and NheI, and the sticky ellds were filled by means of Klenow polymerase. A 0.8 kb CAV DNA fragment was isolated.
The plasmid pAcUW51 was linearized with BamH1, the sticky ends filled by means of Klenow polymerase and finally treated with alkaline phosphatase ~CIP). The 0.8 kB CAV
DNA fragment was ligated at the linearized pAcUW51 DNA.
The orientation of VP2 in pAcUW51 was determined by restriction enzyme analysis. This construct was called pUW-VP2.
The pl~-cm;~ pET-16b-VP1 (Noteborn et al., data not publ;qhe~) contains CAV DN~ sequences of positions 853 to 2319. The CAV DNA insertion contains the complete coding region for the protein VPl flanked by 117 bp 3'-non-coding CAV DNA sequences. The plasmid pET-16b-VPl was treated with the restriction enzymes NdeI and EcoRI, and the sticky ends were filled by means of Klenow polymerase. A
1.45 kb CAV DNA fragment was isolated. The plasmid pUW-VP2 was linearized by EcoRI, the sticky ends filled by means of Klenow polymerase and finally treated by CIP. The 1.45 kb CAV DNA fragment was ligated at the linearized pUW-VP2.
The orientation of VP1 opposite of the plO promoter unit was determined by restriction-enzyme analysis, and the final construct pAcVPl/VP2 is shown in Figure 3.
Construction of rec~mhin~nt-VPl/VP2 baclllovirus.
The open reading frames encoding VPl and VP2 were separately cloned into a single baculovirus transfervector, viz pAcUW51. The CAV sequences encoding VPl are under the regulation of the baculovirus plO
promoter and VP2 under the regulation of the baculovirus CA 0222l~70 l997-l2-0~
wos6/40s31 PCT~L96/00230 poyhedrin promoter. Transfection of Sf9 insect cells occurred with 'naked' baculovirus DNA and transfervector DNA. After homologous recombinantion baculovirues were obtained which had incorporated the VP1/VP2 expression unit, integrated in the polyhedrin region of the recombinant baculovirus, instead of the lacZ unit. The recombinant baculoviruses were characterized for the absence of beta-galactosidase activity and integration of CAV DNA sequences.
Expression of the CAV prote; n~ VP1 and VP2 ; n Sf9 c~lls.
The simultaneous expression of the CAV proteins VP1 and VP2 in Sf9 cells infected with recombinant-VP1/VP2 baculovirus was analyzed by Coomassie-brilliant blue staining and protein labeling with Promix (ICN, USA) or 3H-leucine (Amersham, UK) and PAA-SDS gel electrophoresis.
In the PCT/NL94/00168 it was shown that lysates of insect cells infected with recombi nant-VP1 baculovirus contained a CAV-specific protein of 52 kD and expression of VP2 by recombinant-VP2 baculovirus in infected insect cells produced a major specific product of 30 kDa.
Infection of insect cells with recombinant-VP1/VP2 baculovirus resulted in the synthesis of both the CAV-specific proteins of 52 kD and 30 kD. Both CAV-specific products could be detected as radioactively labeled protein band or Coomassie-brilliant blue stained protein band. The latter result indicates that both products are produced in relatively high levels in recombi nant-VPl/VP2-baculovirus-infected insect cells. Sf9 cells infected with a recombinant-lacZ baculovirus did not contain these CAV-specific proteins.
Thus we have obtained evid~nce that inoculation in hens of crude lysates of recombinant-VP1/VP2-infected Sf9 - 35 cells are able to induce neutralizing antibodies directed against CAV.
CA 0222l~70 l997-l2-0~
Wo 96/40931 PCT/NL96/00230 The role OI' VP2 for the formation of a conformational neutr~lizing epitope of VPl.
As reported in PCT/NL94/00168 and by Koch et al.
(1995), simultaneous synthesis and not simply mixing of 5 recombinant CAV proteins VPl and VP2 is required to obtain a neutralizing and protective immune response. These data suggest that VP2 is a non-structural protein that at some stage of infection is required for virus assembly and/or the correct conformation of VP1, which result(s) in the 10 formation of the neutralizing epitope(s). One explanation of the requirement of VP2 might be that it acts ~s a scaffold protein that is necessary during the assembly of the virion but absent in the final product (Leibowitz and Horwitz, 1975). Examples of scaffold proteins are the IVa2 15 and 39kDa proteins of adenovirus (D'Halluin et al., 1978;
Persson et al., 1979). These proteins act as scaffolds for the formation of the so-called light capsid, but are L~..oved in the next step. VP2 might function in a s;m;1;~r way during the formation of CAV virions. However, at this 20 stage, we cannot entirely exclude that (very) small amounts of VP2 that remained undetected in electroblots of purified CAV preparations (Todd et al., 1990) or in electron microscopic photographs of lysed CAV particles incubated with immunogold-labeled VP2-specific monoclonal 25 antibodies, as described above, associate with VP1 and form conformational neutralizing epitopes. Recently, weak evidence for the presence of VP2 in gradient-purified CAV
was reported (Buchholz, 1994).
In the following experiments, evidence is provided 30 that the neutralizing epitope of VP1 is only (optimal) present, when VP2 is simultaneously synthesized. Insect cells were infected with recombinant-CAV baculoviruses expressing VP1, VP2 (see PCT/NL94/00168) or both VP1 plus VP2. The infected Sf9 cells were harvested 3 or 4 days 35 after infection and used for immunofluorescence tests with the CAV-specific neutralizing monoclonal antibody 132.1.
The cells containing only the CAV-specific protein VP2 did CA 0222l~70 l997-l2-0~
WO96140931 PCT~L96/00230 not react at all with the monoclonal antibody 132.1. Cells cont~;n; ng only VPl revealed a very poor immunofluorescence signal after incubation with monoclonal antibody 132.1. However, insect cells infected with recombinant-VP1/VP2 baculovirus expressing both VP1 and VP2 bound very strongly to the neutralising monoclonal 132.1. PAA-SDS gel electrophoresis of in parallel radioactive-labeled lysates of insect cells expressing VP1, VP2 or VP1 plus VP2, revealed that VP1 is expressed at the same level when expressed only or simultaneously with VP2.
VP1 and VP2 interact temporarily with each other.
The neutralizing epitope of VP1 is only formed when VP2 is present, and therefore is a conformationally distinct epitope. This implies that VP1 and VP2 associate with each other during a short time period. By means of ;mmllnoprecipitations under very mild conditions, we have ~m; ned whether VP1 could associate with VP2. Sf9 insect cells were infected with recombinant baculoviruses, which synthesized VP1, VP2, or VP1 plus VP2.
The results clearly reveal that monoclonal antibody 111.1 precipates VP2 when VP2 is synthesized alone or in the presence of VP1. In the case that besides VP2, VP1 was expres sed also, VP1 co-precipitated to a small extent with VP2. The monoclonal antibody 111.1 did not detectably precipitate VP1, when VP1 was synthesized in the absence of VP2. These data indicate that VP1 and VP2 are (to a relatively small amount) associated to each other. During this association event, VP1 might obtain its conformation resulting in the neutralizing epitope.
Basis for the development of vaccines aaa;nst CAV
infections The above presented results show that for the induction of neutralizing antibodies against CAV, VP1 is required which has a specific conformation. In a CA 02221~70 1997-12-0~
baculovirus expression system, this correct VP1 conformation is only possible, when VP1 plus VP2 or VPl plUS VP2 plus VP3 are simultaneously synthesized.
Denaturation of VP1 with e.g. sodium-dodecyl-sulphate result also in the destruction of it neutralizing epitope, indicating that the VPl neutralizing epitope is an conformational one.
The recombinant CAV products, VP1 plus VP2 or VP1 plus VP2 plus VP3, which will be used for vaccination of laying-hens, can be synthesized by means of the baculovirus system. The CAV proteins can also be synthesized by means of other expression systems, such as yeast cells, via (retro)- viral infection or gene amplification (CHO-dhfr system) in m~mm~l ian cell systems.
In principle, the expression of fragments of VP1 (in combination with VP2 or VP2 and VP3) may be sufficient for the induction of a protective immune response. The fact that 12-mers of VP1 can not react with neutralizing antibodies against CAV indicates that larger VPl fragments 20 are needed for getting the correct VPl conformation to form the neutralizing epitope. However, one should take into account that minor amino-acid mutations or a few amino-acid deletions might not influence the formation of the neutralizing epitope of VPl.
The fact that 2 or 3 proteins encoded by the CAV open reading frames can induce a protective immune respons is also applicable to the development of living virus vectors. The coding sequences for VPl plus VP2 or VPl plus VP2 plus VP3 are then cloned into living virus vectors.
It is also possible that one of the CAV proteins, VPl, VP2 or VP3, separately, but then within the context of a living virus vector, is also suitable for the induction of a protective immune response against CAV
infections. The expression of fragments of one of the abo ve-mentioned CAV proteins by living virus vectors may be sufficient for the induction of a protective immune response.
CA 0222l~70 l997-l2-0~
WO96/40931 PCT~L96/00230 The fact that VP3 causes apoptosis in, i.e. chicken mononuclear cells (PCT/NL94/00168i Noteborn et al., 1994a favors to construct living virus vectors not expres sing VP3. The replication of i.e. Marek_s disease virus might be negatively influenced by VP3-induced apoptosis.
Alternatively, one can produce attenuated CAV
expressing VP1 with the required conformation needed for eliciting a neutralizing and protective immune response agnaist CAV infections.
Co~truction of a rec~mh;n~nt-~nV-VP1/VP2 trAncfçr vector.
The coding sequences for the CAV proteins VP1 and VP2 were cloned into the Marek's disease virus (MDV) transfervector pMD-US10-SV (Koch, unpublished data). The transfervector contains the SV40 early promoter, which are flanked by sequences of the MDV US10 region, and prokaryotic sequences for multiplication in bacteria.
A schematic representa tion of the transfer vector is given in Figure 4.
The CAV coding sequences from position nt 368 to nt 2319 were inserted in the pMD-US10-SV transfervector under the regulation of the Sv40 ealy promoter. This recombinant transfervector was checked by restriction enzyme digestion and is called pMD-US10-SV-VP1/VP2.
By introducing a point-mutation at position 549 {T
was changed into an A) an extra stopcodon has been introduced in the gene encoding VP3 (Noteborn, unpublished data). Therefore, the inserted CAV sequences will only express VP1 and vP2. Indirect-immunofluorescence analysis of chicken embryo fibroblasts (CEF) transfected with the vector pMD-US10-SV-VP1/VP2 proved that VP1 and VP2 were indeed expressed, whereas VP3 was not.
Construction of rec~mhin~nt-VP1/VP2 ~nv.
Using the Ca-phosphate transfection method, recombinant transfer vector pMD-US10-SV-VP1/VP2 DNA was transfected with MDV (Rispens isolate) DNA,in CEF cells.
CA 0222l~70 l997-l2-0~
WO96/40931 PCT~L96/00230 After homologous recombination, recombinant MDVs were obtained, which had incor porated the CAV coding sequences in the the USlO region ~Nakamura et al., 1992). The recombinant-VPl/VP2 MDVs were characterized for the presence of the expression of VP2. By in-parallel plaque purification and ;mmllno-peroxidase analyis using a monoclonal antibody directed against VP2, several 100%-purified recombinant-VPl~VP2 MDV independent strains were obtained.
Char~cter;~at;on of recnmhin~nt-VPl~VP2 ~nv.
The correct integration of the CAV-DNA sequences in the MDV genome was determined by means of PCR and restriction-enzyme analysis. By subsequent passaging of the various purified recombinant-VPl/VP2 MDVs, it was shown that they remained stable. No recombinants were obtained with (partial) loss of the VPl/VP2 expresssion unit.
The simultaneous expression of the CAV proteins VPl and VP2 in CEF cells, which were infected with the recombinant-VPl/VP2 MDV, was proven by indirect immunofluorescence. The monoclonal antibodies CVI-CAV-111.1 (111.1), directed against VP2 and CVI-CAV-132.1 (132.1), directed against VP1 were used.
The monoclonal antibody 132.1 is directed against a neutralizing epitope of VP1. The fact that the neutralizing antibody 132.1 can recognize recombinant-MDV
expressed VP1, co-synthesized with VP2, implies that the required neutralizing epitope is present on MDV-expressed VP1. Therefore, vaccination of chickens with recombinant-VP1/VP2 MDV will result in the induction of a neutralizing/protective antibody response. Besides the synthesis of the CAV VP1 and VP2 proteins, the recombinant-VP1/VP2 MDV will synthesize the MDV proteins required for the induction of a protective immune response against MDV infections.
CA 02221~70 1997-12-0~
WO 96/40931 . PCT/NL'~6/00'~0 Pro~uc~;on of attenuated CAV based on the cloned CAV
genome pCAV/EcoRI.
The CAV-EcoRI clone is used for the production of ~ viable infectious CAV particles. To that end, the complete CAV insert, the 2,319-bp EcoRI fragment has to be isolated from the bacterial sequences and recircularized by DNA
polymerase treatment. Subsequently, e.g. MDCC-MSB1 cells are transfected with the recircularized EcoRI fragments and after several days wild-type CAV will be produced.
One can introduce mutational changes in the CAV
sequences of the CAV-EcoRI clone and isolate, recircularize and transfect in MDCC-MSBl cells. Instead of wild-type CAV, in principle one can produce mutant CAV and if the mutant is less pathogenic, attenuated CAV. The complete strategy for the production of attenuated CAV is shown in Figure 5.
Constrllct;o~ of CAV gen~mes co~tA;ninq mlltate~
promoter/~nh~ncer reaions.
A remarkable feature of the CAV promoter/enhancer region is a sequence of 4 or 5 near-perfect 21-bp repeats, interrupted by an insert of 12-bp (Noteborn et al., 1991).
This region is involved in the regulation of the CAV
transcription (Noteborn et al., 1994b).
For the production of attenuated CAV, we have introduced mutational changes in the 12-bp insert/direct-repeat region of the CAV-EcoR1 clone (Noteborn et al., 1991). The mutated promoter/enhancer region of the wild-type (wt) and the various CAV mutants are shown in Fig. 6. The Nae-mutant contains no 12-bp/direct-repeat region sequences at all. Tnstead of these, a NaeI site (5'-GCCGGC-3') has been introduced, which is given as 'N' in figure 6.
All other mutants contain 4 original direct repeats instead of 5, as is the case for the CAV-EcoRI clone. The various CAV mutants, called '6b'p, '12bp', '24bp' contain changed 12-bp inserts. The mutant 'wt in Nae' and of CA 02221~70 1997-12-0~
WO96/40931 PCT~L96/00230 course the original CAV-EcoRI clone, called 'wt', contain the original 12-bp insert sequences 5'-AAGAGGCGTTCC-3'.
The CAV mutants '6bp', '12bp', '18bp', '24bp' and 'wt in Nae' contain all additional sequences flanking the 12-bp insert/direct-repeat region. At the 5'-site of this region, the linker 5'-GCCCATGT-3', and at the 3'-site the linker 5'-GATCCGCC-3' has ~een introduced.
Mtltate~ CAV a~nomes resl~lts in the production of attenuated infectious CAV.
To detPrmine whether the mutated CAV genomes could produce live CAV particles, firstly the synthesis of VP3 was ~mined. At several timepoints after transfection, a part of the various transfected MDCC-MSBl-cell cultures were aceton-fixed and analysed by indirect immllnofluorescence using a monoclonal antibody directed against VP3. In parallel, 1 ml of each culture was added to 9 ml of fresh RPMI-medium, which was supplemented with 10~ fetal bovine serum.
Approximately 15% and 90% of the cultured MDCC-MSB1 cells, transfected with 'wt' recircularized CAV genome DNA, contained VP3 after 6 days and 11 days (the cells were one time passaged after transfection), respectively.
The CAV mutant genome 'Nae', lacking the complete 12-bp insert/direct-repeat region, was shown not to produce infectious virus particles. Six days after transfection, at most 2~ of the cells produced VP3, which is due to transient expression of the 'Nae' DNA. A simil~r percentage is obtained with expression plasmid pRSV-VP3 30 (Noteborn et al., 1994b) encoding VP3 only, and which are known not to replicate in eukaryotic cells. After 3 weeks and several passages, no VP3 was present anymore in the Nae-DNA transfected MDCC-MSB1 cell cultures.
At various time-intervals after transfection, the percentage of VP3-positive cells of the MDCC-MSB1 cultures, transfected with the mutant-DNA genomes '6bp', 12bp', 18bp, 24bp and 'wt in Nae' was significantly lower CA 0222l~70 l997-l2-0~
WO96/40931 PCT~L96/00230 compared with cultures, transfected with 'wt'-DNA genome.
These data imply that the various CAV mutants replicate less fast than the wild-type CAV. Especially, the mutants '6bp' and '18bp' were reduced in their replication rate.
Most likely, the mutational changes of the 12-bp insert results in the lower virus spead of the mutated CAV. The results of these experiments are shown in Figure 7.
Subsequently, we have infected fresh MDCC-MSB1 cultures with supernatants of cells tran~fected with all 10 ~mi ned mutated CAV-DNA genomes. All supernatants, except the one derived from 'Nae'-DNA-transfected cells~ were proven to contain infectious virus parti cles. For these cultures, infected with the 'mutated-virus' containing supernatants, it could be shown by indirect immunofluorescence, that cells were present containing VP3.
CAV mllt~nts h~ve ~ re~uce~ cvtopa~hoq~n;c effect.
In parallel with the above described detection of VP3 synthesis, the transfected cells wçre analysed whether they had become apoptotic. CAV is known to induce apoptosis, 2-3 days after infection. To that end, the cells were stained with propidium iodide, which stains 'normal' DNA strongly, but apoptotic DNA weakly and/or irregularly. Already, 11 days after transfection almost all MDCC-MSB1 cells transfected with 'wt' DNA were shown to be apoptotic, whereas the majority of the cells, transfected with the various mutated CAV-DNA genome were not. The capacity for inducing apoptosis was shown to be mostly reduced for the CAV mutants '6bp' and '18bp'.
DNA ~lys;~ of att~nl~ted CAV.
By polymerase-chain reaction and sequence analysis of the 12-bp insert/direct-repeat region and flanking sequences, it was shown that the original mutations were not changed for the various CAV mutants '6bp', '12bp', '18bp', '24bp' and 'wt in Nae'. These results indicate CA 02221~70 1997-12-0~
wos6/4o93l PCT~L96/00230 that the various CAV mutants are stable, at least after culturing in MDCC-MSBl for about l month and that indeed these CAV mutants are viable and causing a reduced cytopathogenic effect in cultured chicken T cells.
Southern blot analysis of DNA isolated from MDCC-MSBl cultures, infected with the various CAV mutants, revealed that all viable CAV mutants produced all CAV DNAs, as was described for wild-type CA~. The double-stranded replication intermediate and sing le-stranded DNA were detected for both wild-type as mutated CAV.
Attenuated CAV synthesizes the CAV-specific neutral;zin~
epitope By indirect-immunofluorescence, using the neutralizing monoclonal antibody CVI-CAV 132.l and a monoclonal antibody directed against VP2, viz CVI-CAV
lll.2 and VP3, viz CVI-CAV-85.l, it was shown that all mutated CAV g~nnm~S were able to synthesize the CAV
proteins VPl, VP2 and VP3. Even more important is that the neutralizing monoclo nal antibody 132.l reacted with cells, infected with the various CAV mutants. This finding indicates that the mutated CAVs will produce the required neutralizing CAV-specific epitope, whcih has to be recognized by the immune system of vaccinated chickens as CAV for eliciting a protecvctive immune response.
It can be concluded that based on the CAV clone pCAV-EcoRI, mutated CAV genomes can be made, resulting in the production of viable mutated CAV particles. These CAV
mutants replicate in cultured chicken T cells less fast than wild-type CAV. The cytopa thogenic effect caused by these CAV mutants is also reduced compared to wild-type CAV. The CAV mutants are all able to produce all CAV
proteins resulting in the required neutrali zing epitope on VPl.
Therefore, these CAV mutants are attenuated versions of CAV in the field.
CA 02221~70 1997-12-0~
Description of the Figllres Figure 1 shows the pepscan analysis of the neutralizing monoclonal antibodies of type 132.1 with - peptides (12-mers~ derived from VP1.
Figure 2 shows the pepscan analysis of the - neutralizing monoclonal antibodies of type 132.1 with peptides (12-mers) derived from VP2.
Figure 3 shows the diagrammatic representation of the recombinant transfer pUW-VP1/VP2.
Figure 4 shows the diagrammatic representation of the recombinant transfer vector pMD-US10-SV-VP1/VP2., Figure 5 shows the strategy for the production of attenuated CA~-mutants, based on the plasmid pCAV/EcoR1 containing 2319 bp of wild-type CAV.
Figure 6 shows the schematic structure of the CAV
promoter/enhancer region of the various mutated and wild-type CAV strains.
Figure 7 shows the VP3-expression rates obtained for the various mutant-CAVs and wild-type CAV after tranfection of mutant or wild-type circularized DNA. The VP3-expression rate are given as percentage of VP3-positive MDCC-MSB1 cells.
Figure 8 gives the sequence of CAV.
CA 0222l~70 l997-l2-0~
WO96/40s31 PCT~L96/00230 REFE~N~
1. Boyle, D.B. and Heine, H.G. 1993. Recombinant fowl pox virus vaccines for poultry. Immunology and Cell Biology 71, 391-397.
2. Buchholz, U. Charakterisierung des Huhneranamievirus (CAV mit Hilfe von monoklonal Antikorpern. Dissertation Free University of Berlin, 1994, Journal no 1738, Berlin, Germany.
3. Claessens, J.A.J., Schrier, C.C., Mockett, A.P.A., Jagt, E.H.J.M. and Sondermeijer, P.A.J. 1991. Molecular cloning and sequence analysis of the genome of chicken anemia virus. Journal of General Virology, 72, 2003-2006.
4. D'Halluin, J.C., Martin, G.R., Torpier, G., and Boulanger, P.A. 1978. Adenovirus type 2 assembly analyzed by reversible cross-linking of labile intermediates.
Journal of Virology 26, 198-208.
Journal of Virology 26, 198-208.
5. Gelderblom, H., Kling, S., Lurz, R., Tischer, I. and Von Bulow, V. 1989. Morphological characterization of chicken anamia agent (CAA). Archives of Virology 109, 115-120.
6. Ghe~sen, H.M., Barteling, S.J., and Meloen, R. 1985.
Small peptides induce antibodies with a sequence and structural requirement for binding antigen comparable to antibodies raised against the native protein. Proceedings of National Academy of Sciences USA 82, 178-182.
Small peptides induce antibodies with a sequence and structural requirement for binding antigen comparable to antibodies raised against the native protein. Proceedings of National Academy of Sciences USA 82, 178-182.
7. Graham, F.L. and Van der Eb, A.J. 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52, 456-467.
8. Jeurissen, S.H.M., Janse, M.E., Ekino, S., Nieuwenhuis, P., Koch, G., and De Boer, G.F. (1988).
Monoclonal antibodies as probe for defining cellular subsets in the bone marrow, thymus, bursa of Fabricius, and spleen of the chicken. Veterinary Immunology and Immunopa thology 19, 225-238.
Monoclonal antibodies as probe for defining cellular subsets in the bone marrow, thymus, bursa of Fabricius, and spleen of the chicken. Veterinary Immunology and Immunopa thology 19, 225-238.
9. Jeurissen, S.H.M., Janse, M.E., Van Roozelaar, D.J., Koch, G. and De Boer, G.F. 1992. Susceptibility of thymocytes for infection by chicken anemia virus is CA 0222l~70 l997-l2-0~
WO96/40931 PCT~L96/00230 related to pre- and hat ching development. Developmental Immunology 2, 123-129.
WO96/40931 PCT~L96/00230 related to pre- and hat ching development. Developmental Immunology 2, 123-129.
10. Jeurissen, S.H.M., Wagenaar, F., Pol, J.M.A., Van der Eb, A.J. and Noteborn, M.H.M. (1992a). Chicken anemia virus causes apoptosis of thymocytes after in-vivo infection and of cell lines after in-vitro infection.
Journal of Virology 66, 7383-7388.
Journal of Virology 66, 7383-7388.
11. Kato, A., Fujino, F., Nakamura, T., Ish; h~mA ~ A., and Otaki, Y. 1995. Gene organization of chicken anemia virus.
Virology 209, 480-488.
Virology 209, 480-488.
12. Koch, G., Van Roozelaar, D.J., Verschueren" C.A.J., Van der Eb, A.J., and Noteborn, M.H.M. 1995. Immunogenic and protective properties of chicken anemia virus proteins expressed by baculovirus. Vaccine, 13, 763-770.
13. Leibowitz, J., and Horwitz, M.S. 1975. Synthesis and assembly in adenovirus type 5 temperature-sensitive mutants. Virology 93, 198-208.
14. Maniatis, T., Fritsch, E.F., and Sanbrook, J. (1982).
Molecular Cloning: A Laboratory Manual. CSHL Press, New York, USA.
Molecular Cloning: A Laboratory Manual. CSHL Press, New York, USA.
15. McConnell, C.D.G., Adair, B.M. and McNulty, M.S.
(1993a). Effects of chicken anemia virus on cell-mediated immune function in chickens exposed to the virus by a natural route. Avian Diseases 37, 366-374.
(1993a). Effects of chicken anemia virus on cell-mediated immune function in chickens exposed to the virus by a natural route. Avian Diseases 37, 366-374.
16. McIlroy, S.G., McNulty, M.S., Bruce, D.W., Smyth, J.A., Goodall, E.A. and Alcorn, M.J. (1992). Economic effects of clinical chicken anemia agent infection on profitable broiler production. Avian Diseases 36, 566-574.
17. McNulty, M.S. 1991. Chicken anaemia agent: a review.
Avian Pathology 20, 187-203.
Avian Pathology 20, 187-203.
18. Meehan, B.M., Todd, D., Creelan, J.L., Earle, J.A.P., Hoey, E.M. and McNulty, M.S. 1992. Characterization of viral DNA from cell infecetd with chicken anaemia agent:
sequence analysis of the cloned replicative form and transfection capabilities of cloned genome frag ments.
Archives of Virology, 124, 301-319.
CA 0222l~70 l997-l2-0~
WO96/40931 PCT~L96/00~30 19. Morgan, R.W., Gelb, B. Jr, Pope, C.R. and Sondermeijer, P.J.A. (1993). Efficacy of a herpesvirus of turkeys recombinant vaccine contA;n;ng the fusion gene of Newcastle disease virus: onset of protection and effect of maternal antibodies. Avian Diseases 37, 1026-1032.
sequence analysis of the cloned replicative form and transfection capabilities of cloned genome frag ments.
Archives of Virology, 124, 301-319.
CA 0222l~70 l997-l2-0~
WO96/40931 PCT~L96/00~30 19. Morgan, R.W., Gelb, B. Jr, Pope, C.R. and Sondermeijer, P.J.A. (1993). Efficacy of a herpesvirus of turkeys recombinant vaccine contA;n;ng the fusion gene of Newcastle disease virus: onset of protection and effect of maternal antibodies. Avian Diseases 37, 1026-1032.
20. Nakamura, H., Sakaguchi, M., Hirayama, Y., Miki, N., Yamamoto, M. and Hirai, K. 1992. Protection against Newcastle disease virus by recombinant Marek_s disease virus serotype-l expressing the fusion protein of Newcastle disease virus. Proceedings World_s Poultry Congress Symposium, Ponsen and Looijen, Wageningen, The Netherlands, Volume I, pp 332-338.
21. Nazerian, K., Lee, L.F., Yanagida, N. and Ogawa, R.
(1992). Protection against Marek_s disease by a fowlpox virus recombinant expressing the glycoprotein B of Marek's disease virus. Journal of Virology 66, 1409-1413.
(1992). Protection against Marek_s disease by a fowlpox virus recombinant expressing the glycoprotein B of Marek's disease virus. Journal of Virology 66, 1409-1413.
22. Noteborn, M.H.M. en De Boer, G.F. 1991. Patent application USA/no. 030, 335.
23. Noteborn, M.H.M., De Boer, G.F., Kant, A., Koch, G., Bos, J.L., Zantema, A., and Van der Eb, A.J. 1990.
Expression of avian leukemia virus env-gp85 in Spodoptera frigiperda cells by use o~ a baculovirus expression vector. Journal of General Virology 71, 2641-2648.
Expression of avian leukemia virus env-gp85 in Spodoptera frigiperda cells by use o~ a baculovirus expression vector. Journal of General Virology 71, 2641-2648.
24. Noteborn, M.H.M., De ~3Oer, G.F., Van Roozelaar, D.J., Karreman, C., Kranenburg, O., Vos, J.G., Jeurissen, S.H.M., Hoeben, R.C., Zantema, A., Koch, G., Van Ormondt, H., and Van der Eb, A.J. 1991. Characterization of cloned chicken anemia virus DNA that contain all elements for the infectious replication cycle. Journal of Virology 65, 3131-3139.
25. Noteborn, M.H.M. and Koch, G. 1995. Chicken anaemia virus infection: molecular basis of pathogenicity. Avian Pathology 24, 11-31.
26. Noteborn, M.H.M. and Koch, G. 1994. PCT/NL94/ 001688.
Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefore.
CA 0222l~70 l997-l2-0~
W096/40931 PCT~L96/00230 27. Noteborn, M.H.M., Kranenburg, O., Zantema, A., Koch, G., De Boer, and Van der Eb, A.J. 1992. Transcription of the chicken anemia virus (CAV) genome and synthesis of its 52-kDa protein. Gene 118, 267-271.
Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefore.
CA 0222l~70 l997-l2-0~
W096/40931 PCT~L96/00230 27. Noteborn, M.H.M., Kranenburg, O., Zantema, A., Koch, G., De Boer, and Van der Eb, A.J. 1992. Transcription of the chicken anemia virus (CAV) genome and synthesis of its 52-kDa protein. Gene 118, 267-271.
28. Noteborn, M.H.M., Todd, D., Verschueren, C.A.J., De Gauw, H.W.F.M., Curran, W.L., Veldkamp, S., Douglas, A.J., McNulty, M.S., Van der Eb, A.J., and Koch, G. 1994a. A
single chicken anemia virus protein induces apoptosis.
Journal of Virology 68, 346-371.
single chicken anemia virus protein induces apoptosis.
Journal of Virology 68, 346-371.
29. Noteborn, M.H.M., Veldkamp, S., Verschueren, C.A.J., Van Roozelaar, D.J., Van der Eb, A.J., and Koch,.G. 1994.
Molecular-biological characterization of chicken anemia virus. In: Virus Diseases of Poultry-New and Evolving Pathogens, 195-212.
Molecular-biological characterization of chicken anemia virus. In: Virus Diseases of Poultry-New and Evolving Pathogens, 195-212.
30. Noteborn, M.H.M., Verschueren, C.A.J., Zantema, A., Koch, G. and Van der Eb, A.J. 1994b. Identification of the promoter region of chicken anemia virus (CAV) cont~; n; ng a novel enhancer element. Gene 150, 313-318.
31. Pallister, J., Fahey, K.J., and Sheppard, M. 1994.
Cloning and equencing of the chicken anemia virus (CAV) ORF-3 gene, and the development of an ELIA for the detection of serum antibody to CAV. Veterinary Microbiology 39, 167-178.
Cloning and equencing of the chicken anemia virus (CAV) ORF-3 gene, and the development of an ELIA for the detection of serum antibody to CAV. Veterinary Microbiology 39, 167-178.
32. Persson, H., Mathisen, B., Philipson, L., and Petterson, V. 1979. A maturation protein in adenovirus morphogenesis. Virology 93, 198-208.
33. Phenix, K.V., Meehan, B.M.; Philipson, L. and McNulty, M.S. 1994. Trancriptional analysis and genome expression of chicken anemia virus. Journal of General 30 Virology 75, 905-909.
34. Rispens, B.H., Van Vloten, H., Mastenbroek, N., Maas, H.J.L., and Schat, K.A. 1972. Control of Marek_s disease in the Netherlands. I. Isolation of an avirulent Marek_s disease virus strain (CVI 988) and its use in laboratory - 35 vaccination trials. Avian Diseases 16, 108-125.
35. Soine, C., Watson, S.K., Rybicki, E., Lucio, B., Nordgren, R.M., Parrissh, C.R., and Schat, K.A. 1993.
CA 0222l~70 l997-l2-0~
WO96/40931 PCT~L96/00230 Det~rmin~tion of the detection limit of the polymerase chain reaction for chicken anemia virus. Avian Diseases 37, 467-476.
35. Soine, C., Watson, S.K., Rybicki, E., Lucio, B., Nordgren, R.M., Parrissh, C.R., and Schat, K.A. 1993.
CA 0222l~70 l997-l2-0~
WO96/40931 PCT~L96/00230 Det~rmin~tion of the detection limit of the polymerase chain reaction for chicken anemia virus. Avian Diseases 37, 467-476.
36. Soine, C., Renshaw, R., O'Connell, P.H., Watson, .K., Lucio, B. and Schat, K.A. 1994. Sequence analysis of cell culture- and non-cell culture-adaptable strains of chicken infectious anaemia virus. In: Proceedings of the International Synposium on IBDV and CAV, Eds. E.F. Kaleta, U. Heffels-Re~m~nn and H. hange-Herbst. Rauischholzhausen, Germany. pp 364-365.
37. Todd, D., Creelan, J.L., Mackie, D.P., Rixo~, F., and McNulty, M.S. 1990. Purificati on and biochemical characterisation of chicken anemia agent. Journal of General Virology 71, 819-823.
38. Vielitz, E. and Landgraf, H. (1988).
Anaemia-dermatitis of broilers: field observations on its occurrence, tr~ncmiqsion and prevention. Avian Pathology 17, 113-120.
Anaemia-dermatitis of broilers: field observations on its occurrence, tr~ncmiqsion and prevention. Avian Pathology 17, 113-120.
39. Vielitz, E., Conrad, C., Voss. M., Von Bulow, V., Dorn, P., Bachmeier, J. and Lohren, U. (1991).
Immunization against chicken anaemia agent (CAA)-a field trial. Deutsche Tierarztliche Wochenschrift 98, 144-147.
Immunization against chicken anaemia agent (CAA)-a field trial. Deutsche Tierarztliche Wochenschrift 98, 144-147.
40. Vlak, J.M. and Keus, R.J.A. (1990). Baculovirus expression vector system for pro duction of viral vaccines. In: Viral vaccines. Mizrahi, A. (ed.) Wiley-Liss Inc., Ne~-York, USA. pp 91-123.
41. Von Bulow, V., Fuchs, B., and Bertram, M. 1985.
Unteruchungen uber den Erreger der Infektiosen Anamie bei Huhnerkucken (CAA) in vitro: Vermehrung, Titration, Serumneutralisationstest und indirekter Immunofluorezenstest. Journal of Veterinary Medicine B 32, 679-693.
Unteruchungen uber den Erreger der Infektiosen Anamie bei Huhnerkucken (CAA) in vitro: Vermehrung, Titration, Serumneutralisationstest und indirekter Immunofluorezenstest. Journal of Veterinary Medicine B 32, 679-693.
42. Von Bulow, V., Fuchs, B., Vielitz, B., and Landgraf, H. 1983. Fruhsterblichkeitssyn drom bei Kuken nach Doppelinfektion mit dem Virus des Marekschen Krankheit (MDV) und einen Anamie-Erreger (CAA). Journal of Veterinary Medicine B 30, 742-750.
43. Yuasa, N. 1983. Propagation and infectivity titration of the Gifu-1 strain of chicken anaemia agent in a cell line (MDCC-MSB1) derived from Marek's disease lymphoma.
- National Institute ~n;m~l Health Quarterly 23, 13-20.
- National Institute ~n;m~l Health Quarterly 23, 13-20.
44. Yuasa, N., Taniguchi, T., Goda, M., Shibatanni, M., Imada, T., and Hihara, H. 1983. Isolation of chicken anemia agent with MDCC-MSB1 cells from chickens in the field. National Institute An;m~l Health Quarterly 23, 78-81.
Claims (14)
1. A neutralizing antibody or an antibody fragment or derivative thereof reacting with a conformational epitope of viral protein 1 (VP1) of chicken anaemia virus (CAV) recognized by a monoclonal antibody designated as 132-1, 132-2 or 132-3, as produced by the hybridoma's deposited under no.'s xxxxxx, yyyyyy, zzzzzz at the Institut Pasteur, Paris, France.
2. A conformational neutralizing epitope of viral protein 1 of chicken anaemia virus recognized by an antibody according to claim 1.
3. A method for producing a viral protein 1 comprising a conformational epitope according to claim 2, comprising the expression of said viral protein 1 in one cell together with viral protein 2 of said CAV whereby the genetic information encoding VP1 and the genetic information encoding VP2 are separately present on one recombinant vector.
4. A vector for use in a method according to claim 3 comprising as two separate coding sequences the genetic information encoding VP1 and the genetic information encoding VP2.
5. A vector according to claim 4 which is based on Marek's disease virus vector.
6. A vector according to claim 4 which is based on a baculo virus vector.
7. A method for providing a viral protein 1 comprising a neutralizing conformational epitope according to claim 1, comprising expressing at least a functional part of VP1 and VP2 from genes encoding them, which genes are under control of a regulatory sequence derived from the CAV
sequence upstream of the transcription intitiation site which regulatory sequence is modified to reduce its efficiency.
sequence upstream of the transcription intitiation site which regulatory sequence is modified to reduce its efficiency.
8. A method according to claim 3 or 7 whereby VP1 is provided in the form of virus particles.
9. A method according to claim 7 whereby the modification is in the promoter/enhancer region.
10. A method according to claim 9 whereby the modification is in the 12 base pair insert in the promoter enhancer region.
11. Recombinant virus particles obtainable by a method according to claim 7 -10.
12. A nucleic acid for use in a method according to claim 7 -10 comprising a gene encoding at least a functional part of VP1 and a gene encoding a functional part of VP2, at least one of the genes being inder control of a regulatory sequence which is modified to reduce its efficiency.
13. A diagnostic test kit for detecting or determining the presence of CAV or antibodies to CAV in a sample using an antbody according to claim 1 and/or an epitope according to claim 2.
14. A vaccine for the treatment or prophylaxis of CAV
associated disease comprising an antibody according to claim 1 or an epitope according to claim 2 together with a suitable adjuvans and/or a suitable vehicle for administration.
A vaccinefor the treatment or prophylaxis of CAV
associated disease comprising recombinant virus particles according to claim 11 together with a suitable adjuvans and/or a suitable vehicle for administration.
associated disease comprising an antibody according to claim 1 or an epitope according to claim 2 together with a suitable adjuvans and/or a suitable vehicle for administration.
A vaccinefor the treatment or prophylaxis of CAV
associated disease comprising recombinant virus particles according to claim 11 together with a suitable adjuvans and/or a suitable vehicle for administration.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/480,020 US5932476A (en) | 1990-09-12 | 1995-06-07 | Cloning of chicken anemia virus DNA |
US08/480,020 | 1995-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2221570A1 true CA2221570A1 (en) | 1996-12-19 |
Family
ID=23906352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002221570A Abandoned CA2221570A1 (en) | 1995-06-07 | 1996-06-07 | Neutralizing conformation epitopes of chicken anemia virus |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0832242A1 (en) |
JP (1) | JPH11510367A (en) |
CN (1) | CN1194001A (en) |
AU (1) | AU720640B2 (en) |
CA (1) | CA2221570A1 (en) |
NZ (1) | NZ309172A (en) |
WO (1) | WO1996040931A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7192594B2 (en) | 1997-10-03 | 2007-03-20 | Merial Limited | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
FR2772047B1 (en) | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | GENOMIC SEQUENCE AND POLYPEPTIDES OF CIRCOVIRUS ASSOCIATED WITH PIGLET LOSS DISEASE (MAP), APPLICATIONS TO DIAGNOSIS AND TO PREVENTION AND / OR TREATMENT OF INFECTION |
CA2313806A1 (en) | 1997-12-11 | 1999-06-17 | University Of Saskatchewan | Postweaning multisystemic wasting syndrome virus from pigs |
JP2001275664A (en) * | 2000-02-29 | 2001-10-09 | Akzo Nobel Nv | Chicken anaemia virus having low pathogenicity |
AUPR567401A0 (en) * | 2001-06-14 | 2001-07-12 | University Of Melbourne, The | Circovirus vaccines |
WO2004091491A2 (en) * | 2003-04-10 | 2004-10-28 | Transform Pharmaceuticals, Inc. | Profiling conformational variants, antibody compositions and methods of using the same |
EP4091629A1 (en) | 2013-09-25 | 2022-11-23 | Zoetis Services LLC | Pcv2b divergent vaccine composition and methods of use |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69101683T2 (en) * | 1990-07-30 | 1994-07-21 | Akzo Nv | Recombinant Mareks disease virus. |
NL9002008A (en) * | 1990-09-12 | 1992-04-01 | Stichting Centr Diergeneeskund | RECOMBINANT DNA AND RNA AND PRODUCTS DERIVED THEREFROM. |
NL9301272A (en) * | 1993-07-20 | 1995-02-16 | Aesculaap Bv | Chicken Anemia Virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or coding sequences of that virus. |
ZA918426B (en) * | 1990-10-31 | 1992-12-30 | Akzo Nv | Chicken anemia virus vaccine and diagnostic |
-
1996
- 1996-06-07 WO PCT/NL1996/000230 patent/WO1996040931A1/en not_active Application Discontinuation
- 1996-06-07 NZ NZ309172A patent/NZ309172A/en unknown
- 1996-06-07 EP EP96916379A patent/EP0832242A1/en not_active Withdrawn
- 1996-06-07 CN CN96195434A patent/CN1194001A/en active Pending
- 1996-06-07 CA CA002221570A patent/CA2221570A1/en not_active Abandoned
- 1996-06-07 JP JP9500328A patent/JPH11510367A/en active Pending
- 1996-06-07 AU AU59137/96A patent/AU720640B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
CN1194001A (en) | 1998-09-23 |
NZ309172A (en) | 1999-11-29 |
WO1996040931A1 (en) | 1996-12-19 |
AU5913796A (en) | 1996-12-30 |
JPH11510367A (en) | 1999-09-14 |
AU720640B2 (en) | 2000-06-08 |
EP0832242A1 (en) | 1998-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Koch et al. | Immunogenic and protective properties of chicken anaemia virus proteins expressed by baculovirus | |
M. Noteborn et al. | Chicken anaemia virus infection: molecular basis of pathogenicity | |
RU2389506C2 (en) | Pcv-2 vaccine | |
Yao et al. | Induction of apoptosis in vitro by the 17-kDa nonstructural protein of infectious bursal disease virus: possible role in viral pathogenesis | |
Neubauer et al. | Analysis of the contributions of the equine herpesvirus 1 glycoprotein gB homolog to virus entry and direct cell-to-cell spread | |
AU703187B2 (en) | Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor | |
US5491073A (en) | Cloning of chicken anaemia DNA | |
AU720640B2 (en) | Neutralizing conformational epitopes of chicken anemia virus | |
US6071520A (en) | Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor | |
Ghiasi et al. | Baculovirus expressed herpes simplex virus type 1 glycoprotein C protects mice from lethal HSV-1 infection | |
US20020119527A1 (en) | Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines | |
Scott et al. | Characterisation of a chicken anaemia virus variant population that resists neutralisation with a group-specific monoclonal antibody | |
US20050100552A1 (en) | Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor | |
US6217870B1 (en) | Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1 VP2 and VP3 or sequences of that virus coding therefor | |
US5789567A (en) | Chicken infectious anemia virus vaccine | |
EP1539808B1 (en) | gM-NEGATIVE EHV-MUTANTS WITHOUT HETEROLOGOUS ELEMENTS | |
MXPA97009851A (en) | Epithopes conformational neutralizers of poem anemia viruses | |
WO1996001116A9 (en) | Chicken infectious anemia virus vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |